Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Researchers.
- Curriculum.
- Publications.
- Projects.
- Presentations.
- Advised theses.
Institutions.
Projects.
Publications.
Partners.
Sponsors.
Equipment.
Knowhow.
Fields of Research.

Richtig Erika |

Publications

** = Publications listed in SCI/SSCI/Pubmed

2025

Full paper/article (Journal)

** Eigentler, T; Thomas, I; Samoylenko, I; Erdmann, M; Heinzerling, L; Ochsenreither, S; Krauss, J; Oberoi, A; Robert, C; Lebbe, C; Martin-Liberal, J; Koch, L; Richtig, E; Terheyden, P; Weishaupt, C; Mohr, P; Semiletova, Y; Perez, CL; Brossart, P; Bauernfeind, FG; Fluck, M; Poltoratskiy, A; Sekacheva, M; Soria, A; Schmitt-Bormann, B; Gonzalez, M; Hess, J; Wengenmayer, P; Seibel, T; Koch, SD; Quintini, G; Codó, P; Falk, M; Schönborn-Kellenberger, O; Gnad-Vogt, U Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma
J IMMUNOTHER CANCER. 2025; 13(2): e009352 Doi: 10.1136/jitc-2024-009352 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** Hauschild, A; Garbe, C; Ascierto, PA; Demidov, L; Dreno, B; Dummer, R; Eggermont, A; Forsea, AM; Gebhardt, C; Gershenwald, JE; Hamid, O; Hoeller, C; Kandolf, L; Kaufmann, R; Kirkwood, JM; Lebbé, C; Long, GV; Malvehy, J; Martin-Algarra, S; McArthur, G; Neyns, B; Richtig, E; Robert, C; Schadendorf, D; Scolyer, R; Sondak, VK; Wainstein, A; Weichenthal, M; Nuti, P, , Melanoma, World, Society, Study, Group Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey.
Lancet Oncol. 2025; 26(1): 12-14. Doi: 10.1016/S1470-2045(24)00627-2
Web of Science PubMed FullText FullText_MUG

** Schumann, K; Klespe, KC; Mauch, C; Loquai, C; Schultheis, U; Börger, S; Thiem, A; Emmert, S; Hoellwerth, M; Koelbinger, P; Nguyen, VA; Wanner, M; Richtig, E; Peitsch, WK; Harth, W; Zenderowski, V; Braun, AD; Mengoni, M; Dummer, R; Mangana, J; Maul, LV; Meis, F; Rappersberger, K; Persa, OD; Biedermann, T; Posch, C Switching PD-1 to BRAF + MEK inhibition improves recurrence-free survival in patients receiving a second course of adjuvant melanoma therapy.
J Eur Acad Dermatol Venereol. 2025; Doi: 10.1111/jdv.20708
Web of Science PubMed FullText FullText_MUG

** Theiler-Schwetz, V; Trummer, C; Schmitt, L; Terbuch, A; Obermayer-Pietsch, B; Richtig, E; Pilz, S High-dose glucocorticoid treatment vs. glucocorticoid replacement in immune checkpoint inhibitor associated hypophysitis (CORTICI): an open, randomised controlled trial.
Ann Med. 2025; 57(1): 2453829 Doi: 10.1080/07853890.2025.2453829 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** Zager, JS; Orloff, M; Ferrucci, PF; Choi, J; Eschelman, DJ; Glazer, ES; Ejaz, A; Howard, JH; Richtig, E; Ochsenreither, S; Reddy, SA; Lowe, MC; Beasley, GM; Gesierich, A; Bender, A; Gschnell, M; Dummer, R; Rivoire, M; Arance, A; Fenwick, SW; Sacco, JJ; Haferkamp, S; Weishaupt, C; John, J; Wheater, M; Ottensmeier, CH An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma.
Ann Surg Oncol. 2025; Doi: 10.1245/s10434-025-17231-x
Web of Science PubMed FullText FullText_MUG

2024

Full paper/article (Journal)

** Ascierto, PA; Casula, M; Bulgarelli, J; Pisano, M; Piccinini, C; Piccin, L; Cossu, A; Mandalà, M; Ferrucci, PF; Guidoboni, M; Rutkowski, P; Ferraresi, V; Arance, A; Guida, M; Maiello, E; Gogas, H; Richtig, E; Fierro, MT; Lebbe, C; Helgadottir, H; Queirolo, P; Spagnolo, F; Tucci, M; Del Vecchio, M; Cao, MG; Minisini, AM; De Placido, S; Sanmamed, MF; Mallardo, D; Paone, M; Vitale, MG; Melero, I; Grimaldi, AM; Giannarelli, D; Dummer, R; Sileni, VC; Palmieri, G Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial
NAT COMMUN. 2024; 15(1): 146 Doi: 10.1038/s41467-023-44475-6 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** Ascierto, PA; Mandalà, M; Ferrucci, PF; Guidoboni, M; Rutkowski, P; Ferraresi, V; Arance, A; Guida, M; Maiello, E; Gogas, H; Richtig, E; Quaglino, P; Lebbé, C; Helgadottir, H; Queirolo, P; Spagnolo, F; Tucci, M; Del, Vecchio, M; Gonzalez-Cao, M; Minisini, AM; De, Placido, S; Sanmamed, MF; Casula, M; Bulgarelli, J; Pisano, M; Piccinini, C; Piccin, L; Cossu, A; Mallardo, D; Paone, M; Vitale, MG; Melero, I; Grimaldi, AM; Giannarelli, D; Palmieri, G; Dummer, R; Sileni, VC Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma.
NEJM Evid. 2024; 3(10): EVIDoa2400087 Doi: 10.1056/EVIDoa2400087
PubMed FullText FullText_MUG

** Brandlmaier, M; Hoellwerth, M; Silly, T; Hoeller, C; Koch, L; Richtig, E; Binder, K; Lange-Asschenfeldt, B; Barta, M; Schmid-Simbeck, M; Froehlich, F; Dummer, R; Muigg, L; Hitzl, W; Koelblinger, P Immune checkpoint inhibitor-induced pancreatic enzyme elevation in melanoma patients: Incidence, management and therapy-A multicentre analysis.
J Eur Acad Dermatol Venereol. 2024; Doi: 10.1111/jdv.20384
Web of Science PubMed FullText FullText_MUG

** Moik, F; Riedl, JM; Barth, D; Berton, F; Fink, M; Englisch, C; Hoeller, C; Fuereder, T; Ay, L; Pabinger, I; Richtig, E; John, N; Kostmann, SM; Jost, PJ; Gerger, A; Terbuch, A; Preusser, M; Ay, C Early Change in C-Reactive Protein and Venous Thromboembolism in Patients Treated With Immune Checkpoint Inhibitors
JACC-CARDIOONCOL. 2024; 6(6): 965-975. Doi: 10.1016/j.jaccao.2024.09.007 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** Richtig, E; Nguyen, VA; Koelblinger, P; Wolf, I; Kehrer, H; Saxinger, W; Ressler, JM; Weinlich, G; Meyersburg, D; Hafner, C; Jecel-Grill, E; Kofler, J; Lange-Asschenfeldt, B; Weihsengruber, F; Rappersberger, K; Svastics, N; Gasser, K; Seeber, A; Kratochvill, F; Nagler, S; Mraz, B; Hoeller, C Dabrafenib plus trametinib in unselected advanced BRAF V600-mut melanoma: a non-interventional, multicenter, prospective trial.
Melanoma Res. 2023; Doi: 10.1097/CMR.0000000000000948 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** Schörghofer, D; Vock, L; Mirea, MA; Eckel, O; Gschwendtner, A; Neesen, J; Richtig, E; Hengstschläger, M; Mikula, M Late stage melanoma is hallmarked by low NLGN4X expression leading to HIF1A accumulation.
Br J Cancer. 2024; Doi: 10.1038/s41416-024-02758-9 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** Zager, JS; Orloff, M; Ferrucci, PF; Choi, J; Eschelman, DJ; Glazer, ES; Ejaz, A; Howard, JH; Richtig, E; Ochsenreither, S; Reddy, SA; Lowe, MC; Beasley, GM; Gesierich, A; Bender, A; Gschnell, M; Dummer, R; Rivoire, M; Arance, A; Fenwick, SW; Sacco, JJ; Haferkamp, S; Weishaupt, C; John, J; Wheater, M; Ottensmeier, CH Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.
Ann Surg Oncol. 2024; Doi: 10.1245/s10434-024-15293-x [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Correction

** Zager, JS; Orloff, M; Ferrucci, PF; Choi, J; Eschelman, DJ; Glazer, ES; Ejaz, A; Howard, JH; Richtig, E; Ochsenreither, S; Reddy, SA; Lowe, MC; Beasley, GM; Gesierich, A; Bender, A; Gschnell, M; Dummer, R; Rivoire, M; Arance, A; Fenwick, SW; Sacco, JJ; Haferkamp, S; Weishaupt, C; John, J; Wheater, M; Ottensmeier, CH Correction: Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.
Ann Surg Oncol. 2024; Doi: 10.1245/s10434-024-15886-6 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Abstract (Journal)

** Zager, JS; Orloff, M; Ferrucci, PF; Choi, J; Eschelman, DJ; Glazer, ES; Ejaz, A; Howard, JH; Richtig, E; Ochsenreither, S; Reddy, SA; Lowe, MC; Beasley, GM; Gesierich, A; Bender, A; Gschnell, M; Dummer, R; Rivoire, M; Arance, A; Fenwick, SW; Sacco, JJ; Haferkamp, S; Weishaupt, C; John, J; Wheater, M; Ottensmeier, CH ASO Visual Abstract: Efficacy and Safety of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter, Phase 3 Study.
Ann Surg Oncol. 2024; Doi: 10.1245/s10434-024-15421-7
Web of Science PubMed FullText FullText_MUG

** Zager, JS; Orloff, MM; Ferrucci, PF; Choi, JS; Eschelman, DJ; Glazer, ES; Ejaz, A; Richtig, E; Ochsenreither, S; Reddy, SA; Lowe, MC; Beasley, G; Gesierich, AH; Gschnell, M; Dummer, R; Arance, AM; Fenwick, SW; John, J; Wheater, M; Ottensmeier, CHH Melphalan/hepatic delivery system versus best available care in patients with unresectable metastatic uveal melanoma: Randomized FOCUS trial results
J CLIN ONCOL. 2024; 42(16):-ASCO 2024, Annual Meeting; Mai 31 - Juni 4, 2024; Chicago, USA. [Poster]
Web of Science

Comment

** Richtig, G; Richtig, E New ways to strengthen old risk factors.
J Eur Acad Dermatol Venereol. 2024; 38(1): 13-14. Doi: 10.1111/jdv.19585
Web of Science PubMed FullText FullText_MUG

2023

Full paper/article (Journal)

** Ascierto, PA; Mandalà, M; Ferrucci, PF; Guidoboni, M; Rutkowski, P; Ferraresi, V; Arance, A; Guida, M; Maiello, E; Gogas, H; Richtig, E; Fierro, MT; Lebbè, C; Helgadottir, H; Queirolo, P; Spagnolo, F; Tucci, M; Del, Vecchio, M; Gonzales, Cao, M; Minisini, AM; De, Placido, S; Sanmamed, MF; Mallardo, D; Curvietto, M; Melero, I; Palmieri, G; Grimaldi, AM; Giannarelli, D; Dummer, R; Chiarion, Sileni, V Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial.
J Clin Oncol. 2023; 41(2): 212-221. Doi: 10.1200/JCO.21.02961
Web of Science PubMed FullText FullText_MUG

** Barth, DA; Moik, F; Steinlechner, S; Posch, F; Mayer, MC; Sandner, AM; Berton, F; Schlintl, V; Koch, L; John, N; Wurm, R; Pichler, M; Bauernhofer, T; Reimann, P; Wohlkönig, C; Richtig, E; Winder, T; Preusser, M; Jost, PJ; Ay, C; Gerger, A; Terbuch, A; Riedl, JM Early kinetics of C reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: a multicenter cohort study.
J Immunother Cancer. 2023; 11(12): Doi: 10.1136/jitc-2023-007765 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** Dummer, R; Corrie, P; Gutzmer, R; Meniawy, TM; Del Vecchio, M; Lebbé, C; Guida, M; Dutriaux, C; Dreno, B; Meyer, N; Ferrucci, PF; Dalle, S; Khattak, MA; Grob, JJ; Briscoe, K; Larkin, J; Mansard, S; Lesimple, T; Guidoboni, M; Sabatini, S; Richtig, E; Herbst, R; Lobo, M; Askelson, M; Ascierto, PA; Maio, M First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401
J CLIN ONCOL. 2023; 41(23): 3917-+. Doi: 10.1200/JCO.22.02199
Web of Science PubMed FullText FullText_MUG

** Gabriel, M; Trapp, EM; Rohrer, P; Trapp, M; Schwantzer, G; Mester, A; Richtig, E; Schwab, C; Langmann, G; Egger, J; Mayer-Xanthaki, C Coping and vegetative reactivity in uveal melanoma
SPEKTRUM AUGENHEILKD. 2023; Doi: 10.1007/s00717-023-00552-1
Web of Science FullText FullText_MUG

** Lang, R; Welponer, T; Richtig, E; Wolf, I; Hoeller, C; Hafner, C; Nguyen, VA; Kofler, J; Barta, M; Koelblinger, P; Hitzl, W; Emberger, M; Laimer, M Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma (NIVOSQUACS study)-Phase II data covering impact of concomitant haematological malignancies
J EUR ACAD DERMATOL. 2023; Doi: 10.1111/jdv.19218
Web of Science PubMed FullText FullText_MUG

** Richtig, G; Berger, M; Koeller, M; Richtig, M; Richtig, E; Scheffel, J; Maurer, M; Siebenhaar, F Predatory journals: Perception, impact and use of Beall's list by the scientific community-A bibliometric big data study.
PLoS One. 2023; 18(7): e0287547 Doi: 10.1371/journal.pone.0287547 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** Robinson, I; Hochmair, MJ; Schmidinger, M; Absenger, G; Pichler, M; Nguyen, VA; Richtig, E; Rainer, BM; Ay, L; Jansen, C; Pacífico, C; Knabl, A; Sladek, B; Gasche, N; Valipour, A Assessing the Performance of a Novel Stool-Based Microbiome Test That Predicts Response to First Line Immune Checkpoint Inhibitors in Multiple Cancer Types.
Cancers (Basel). 2023; 15(13): Doi: 10.3390/cancers15133268 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** Schumann, K; Mauch, C; Klespe, KC; Loquai, C; Nikfarjam, U; Schlaak, M; Akçetin, L; Kölblinger, P; Hoellwerth, M; Meissner, M; Mengi, G; Braun, AD; Mengoni, M; Dummer, R; Mangana, J; Sindrilaru, MA; Radmann, D; Hafner, C; Freund, J; Rappersberger, K; Weihsengruber, F; Meiss, F; Reinhardt, L; Meier, F; Rainer, B; Richtig, E; Ressler, JM; Höller, C; Eigentler, T; Amaral, T; Peitsch, WK; Hillen, U; Harth, W; Ziller, F; Schatton, K; Gambichler, T; Susok, L; Maul, LV; Läubli, H; Debus, D; Weishaupt, C; Börger, S; Sievers, K; Haferkamp, S; Zenderowski, V; Nguyen, VA; Wanner, M; Gutzmer, R; Terheyden, P; Kähler, K; Emmert, S; Thiem, A; Sachse, M; Gercken-Riedel, S; Kaune, KM; Thoms, KM; Heinzerling, L; Heppt, MV; Tratzmiller, S; Hoetzenecker, W; Öllinger, A; Steiner, A; Peinhaupt, T; Podda, M; Schmid, S; Wollina, U; Biedermann, T; Posch, C Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland.
J Eur Acad Dermatol Venereol. 2023; 37(5):894-906 Doi: 10.1111/jdv.18779
Web of Science PubMed FullText FullText_MUG

Short report/Letter

** Buchacher, L; Richtig, G; Dernoscheg, M; Richtig, E; Koch, L Permanent dose reduction due to adverse reactions does not decrease efficacy of BRAF/MEK inhibition in metastatic melanoma.
J Eur Acad Dermatol Venereol. 2023; 37(5):e605-e607 Doi: 10.1111/jdv.18871
Web of Science PubMed FullText FullText_MUG

** Grossschaedl, K; Vallant, C; Dernoscheg, MT; Richtig, M; Öllinger, A; Balakirski, G; Wilsmann-Theis, D; Nguyen, VA; Weinlich, G; Tsiogka, A; Koelblinger, P; Scheffel, J; Richtig, E; Richtig, G Usage and benefit of the Internet as a source of information on disease and therapy in dermatology.
J Dtsch Dermatol Ges. 2023; 21(11): 1383-1386. Doi: 10.1111/ddg.15199
Web of Science PubMed FullText FullText_MUG

** Grossschaedl, K; Vallant, C; Dernoscheg, MT; Richtig, M; Öllinger, A; Balakirski, G; Wilsmann-Theis, D; Nguyen, VA; Weinlich, G; Tsiogka, A; Koelblinger, P; Scheffel, J; Richtig, E; Richtig, G [Verwendung und Nutzen des Internets als Informationsquelle für Erkrankungen und Therapien in der Dermatologie: Usage and benefit of the Internet as a source of information on disease and therapy in dermatology].
J Dtsch Dermatol Ges. 2023; 21(11): 1383-1386. Doi: 10.1111/ddg.15199_g
PubMed FullText FullText_MUG

Abstract (Journal)

** George, M; Brandl, WT; Richtig, E; Richtig, G; Wadsack, C; Hirschmugl, B INTERPLAY BETWEEN PREGNANCY ASSOCIATED MELANOMA CELLS AND PLACENTAL TISSUE
PLACENTA. 2023; 140: E76-E76.-Annual Meeting of the International-Federation-of-Placenta-Associations (IFPA); SEP 05-08, 2023; Rotorua, NEW ZEALAND. [Poster]
Web of Science

** Richtig, E; Stangl, J; Binder, B; Schadelbauer, E; Avian, A; Cerroni, L Melanoma in children and adolescents - data from the University Hospital Graz
J DTSCH DERMATOL GES. Abstracts. 2023; 21(S4):110-110.-33. Deutschen Hautkrebskongresses (ADO-Jahrestagung); SEP 6-9, 2023; Hamburg, GERMANY. [Oral Communication]
Web of Science

2022

Full paper/article (Journal)

** Winter, R; Tuca, A; Wurzer, P; Schaunig, C; Sawetz, I; Holzer-Geissler, JCJ; Gmainer, DG; Luze, H; Friedl, H; Richtig, E; Kamolz, LP; Lumenta, DB Suction Drain Volume following Axillary Lymph Node Dissection for Melanoma-When to Remove Drains? A Retrospective Cohort Study
J PERS MED. 2022; 12(11): 1862 Doi: 10.3390/jpm12111862 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Short report/Letter

** Buchacher, L; Richtig, G; Schöffl, C; Richtig, E; Koch, L Long-term adherence to melanoma follow-up examinations - a telephone survey.
J Eur Acad Dermatol Venereol. 2022; 36(9):e710-e712 Doi: 10.1111/jdv.18177
Web of Science PubMed FullText FullText_MUG

Abstract (Journal)

** Eigentler, T; Samoylenko, I; Ochsenreither, S; Richtig, E; Thomas, I; Erdmann, M; Lebbe, C; Soto-Castillo, JJ; Terheyden, P; Poltoratskiy, A; Sekacheva, M; Semiletova, Y; Henze, J; Schmitt-Bormann, B; Codo, P; Falk, M; Gnad-Vogt, U INTRATUMORALLY ADMINISTERED CV8102 IN PATIENTS WITH ADVANCED SOLID TUMORS: PRELIMINARY RESULTS FROM ONGOING EXPANSION PART IN STUDY 008
J IMMUNOTHER CANCER. 2022; 10: A818-A818. Doi: 10.1136/jitc-2022-SITC2022.0786 [Poster]
Web of Science FullText FullText_MUG

** Gonzalez, M; Wengenmayer, P; Samoylenko, I; Ochsenreither, S; Richtig, E; Thomas, I; Erdmann, M; Lebbe, C; Martin-Liberal, J; Terheyden, P; Poltoratskiy, A; Sekacheva, M; Semiletova, Y; Eigentler, T; Schmitt-Bormann, B; Vahrenhorst, D; Kays, SK; Seibel, T; Quintini, G; Scheel, B; Falk, M; Gnad-Vogt, U; Codo, P IMMUNE PROFILING OF PATIENTS WITH ADVANCED MELANOMA INTRATUMORALLY TREATED WITH CV8102 AS A SINGLE-AGENT OR IN COMBINATION WITH ANTIPD-1 ANTIBODIES - RESULTS OF A PHASE I TRIAL EXPANSION
J IMMUNOTHER CANCER. 2022; 10: A816-A816.-SITC 37th Annual Meeting (SITC 2022). ; Nov 8-12, 2022; Boston, USA. Doi: 10.1136/jitc-2022-SITC2022.0784 [Poster]
Web of Science FullText FullText_MUG

** Hochmair, M; Schmidinger, M; Ay, L; Robinson, I; Absenger, G; Pichler, M; Nguyen, VA; Richtig, E; Rainer, B; Jansen, C; Sladek, B; Knabl, A; Gasche, N; Valipour, A BiomeOne: multi-center Validation of a new microbiome-based Biomarker to predict Response to Cancer Immunotherapy
ONCOL RES TREAT. 2022; 45(SUPPL 2):229-229.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie; Okt 7-10, 2022; Wien. [Poster]
Web of Science

** Lang, R; Koelblinger, P; Richtig, E; Wolf, I; Hoeller, C; Hafner, C; Nguyen, VA; Kofler, J; Barta, M; Hitzl, W; Laimer, M Efficacy and safety of nivolumab for locally advanced or metastatic cutaneous cell carcinoma (NIVOSQUACS trial).
J CLIN ONCOL. 2022; 40(16):-ASCO Annual Meeting; Jun 3-7,2022; Chicago, USA. [Poster]
Web of Science

** Richtig, E; Loquai, C; Forschner, A; Gutzmer, R; Hassel, JC; Utikal, J; Haferkamp, S; Meier, FE; Debus, D; Dummer, R; Von Moos, RAF; Thompson, J; Gengenbacher, L; Michielin, O; Hoeller, C; Schadendorf, D Encorafenib plus binimetinib in patients with locally advanced, unresectable, or metastatic BRAF(V600)-mutant melanoma: Updated data from the multicenter, multinational, prospective, non-interventional longitudinal study BERING(MELANOMA).
J CLIN ONCOL. 2022; 40(16):-ASCO Annual Meeting; Jun 3-7, 2022; Chicago, USA. [Poster]
Web of Science

** Richtig, E; Loquai, C; Forschner, A; Gutzmer, R; Hassel, JC; Utikal, JS; Haferkamp, S; Meier, F; Debus, D; Dummer, R; Von Moos, RAF; Thompson, J; Gengenbacher, L; Michie-Lin, O; Hoeller, C; Schadendorf, D Encorafenib plus binimetinib in patients with locally advanced, unresectable, or metastatic BRAFV600-mutant melanoma: updated data from the long-term, multicenter, multinational, prospective, noninterventional BERING(MELANOMA) study
J DTSCH DERMATOL GES. 2022; 20: 96-97.-32. Deutschen Hautkrebskongresses (ADO‐Jahrestagung), 14.–17. September 2022; Sep 14-17, 2022; Hannover, Deutschland. [Poster]
Web of Science

** Riedl, JM; Barth, D; Steinlechner, S; Moik, F; Posch, F; Schlintl, V; Mayer, MC; Sandner, AM; Berton, F; Koch, L; John, N; Wurm, R; Pichler, M; Absenger, G; Jost, PJ; Wohlkonig, C; Richtig, E; Winder, T; Gerger, A; Terbuch, A Early CRP Kinetics after Initiation of Immune Checkpoint Inhibitors is a predictive Biomarker for Treatment Response independent of the Tumor Antity
ONCOL RES TREAT. 2022; 45(SUPPL 2):228-228.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie; Okt 7-10, 2022; Wien. [Poster]
Web of Science

** Robinson, I; Schmidinger, M; Hochmair, MJ; Ay, L; Absenger, G; Pichler, M; Nguyen, VAF; Richtig, E; Rainer, B; Jansen, C; Sladek, B; Knabl, A; Gasche, N; Valipour, A BiomeOne: Multi-centric validation of a novel microbiome-based biomarker to predict response to cancer immunotherapy
ANN ONCOL. 2022; 33(7):S592-S592.-Annual Meeting of the European-Society-for-Medical-Oncology (ESMO); SEP 09-13, 2022; ELECTR NETWORK. Doi: 10.1016/j.annonc.2022.07.149 [Poster]
Web of Science FullText FullText_MUG

** Wagner, N; Lenders, MM; Kuhl, K; Reinhardt, L; Fuchss, M; Ring, N; Richtig, G; Ebel, C; Andre, F; Stager, R; Zellweger, C; Sturmer, SH; Lang, R; Paar, M; Gussek, P; Kimeswenger, S; Oellinger, A; Amaral, T; Forschner, A; Leiter-Stoppke, U; Weide, B; Gassenmaier, M; Schraag, A; Klumpp, B; Hoetzenecker, W; Ziemer, M; Berking, C; Mangana, J; Nguyen, VA; Terheyden, P; Richtig, E; Loquai, C; Diem, S; Cozzio, A; Rocken, M; Garbe, C; Gebhardt, C; Meier, F; Eigentler, T; Flatz, L Site-specific tumor response and survival in patients with metastatic melanoma receiving immune checkpoint inhibition or targeted therapy: implications for treatment choice
J DTSCH DERMATOL GES. 2022; 20: 3-4.-32. Deutschen Hautkrebskongresses (ADO‐Jahrestagung), 14.–17. September 2022; Sep 14-17, 2022; Hannover, Deutschland. [Poster]
Web of Science

2021

Full paper/article (Journal)

** Berger, M; Thueringer, A; Franz, D; Dandachi, N; Talakić, E; Richtig, G; Richtig, E; Rohrer, PM; Koch, L; Wolf, IH; Koch, C; Rainer, BM; Koeller, M; Pichler, M; Gerritsmann, H; Kashofer, K; Aigelsreiter, A Circulating Tumor DNA as a Marker for Treatment Response in Metastatic Melanoma Patients Using Next-Generation Sequencing-A Prospective Feasibility Study.
Cancers (Basel). 2021; 13(12): Doi: 10.3390/cancers13123101 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** Chen, MY; Werner, F; Wagner, C; Simon, M; Richtig, E; Mertz, KD; Griss, J; Wagner, SN Spatiotemporal Analysis of B Cell- and Antibody Secreting Cell-Subsets in Human Melanoma Reveals Metastasis-, Tumor Stage-, and Age-Associated Dynamics
FRONT CELL DEV BIOL. 2021; 9: 677944 Doi: 10.3389/fcell.2021.677944 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** COVIDSurg, Collaborative Machine learning risk prediction of mortality for patients undergoing surgery with perioperative SARS-CoV-2: the COVIDSurg mortality score.
Br J Surg. 2021; 108(11): 1274-1292. Doi: 10.1093/bjs/znab183 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** Koelblinger, P; Hoellwerth, M; Dernoscheg, MT; Koch, L; Richtig, E; Wanner, M; Nguyen, VA; Ostermann, H; Bauer, JW; Laimer, M Adjuvant anti-PD-1 antibody treatment in stage III/IV melanoma: real-world experience and health economic considerations
J DTSCH DERMATOL GES. 2021; Doi: 10.1111/ddg.14511 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** Ressler, JM; Karasek, M; Koch, L; Silmbrod, R; Mangana, J; Latifyan, S; Aedo-Lopez, V; Kehrer, H; Weihsengruber, F; Koelblinger, P; Posch, C; Kofler, J; Michielin, O; Richtig, E; Hafner, C; Hoeller, C Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.
J Immunother Cancer. 2021; 9(2): Doi: 10.1136/jitc-2020-001701 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** Sadoghi, B; Schmid-Zalaudek, K; Zalaudek, I; Fink-Puches, R; Niederkorn, A; Wolf, I; Rohrer, P; Richtig, E Prevalence of nevi, atypical nevi, and lentigines in relation to tobacco smoking.
PLoS One. 2021; 16(7): e0254772 Doi: 10.1371/journal.pone.0254772 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** Schrom, S; Hebesberger, T; Wallner, SA; Anders, I; Richtig, E; Brandl, W; Hirschmugl, B; Garofalo, M; Bernecker, C; Schlenke, P; Kashofer, K; Wadsack, C; Aigelsreiter, A; Heitzer, E; Riedl, S; Zweytick, D; Kretschmer, N; Richtig, G; Rinner, B MUG Mel3 Cell Lines Reflect Heterogeneity in Melanoma and Represent a Robust Model for Melanoma in Pregnancy.
Int J Mol Sci. 2021; 22(21): Doi: 10.3390/ijms222111318 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** Steeb, T; Wessely, A; Alter, M; Bayerl, C; Bender, A; Bruning, G; Dabrowski, E; Debus, D; Devereux, N; Dippel, E; Drexler, K; Dücker, P; Dummer, R; Emmert, S; Elsner, P; Enk, A; Gebhardt, C; Gesierich, A; Goebeler, M; Goerdt, S; Goetze, S; Gutzmer, R; Haferkamp, S; Hansel, G; Hassel, JC; Heinzerling, L; Kähler, KC; Kaume, KM; Krapf, W; Kreuzberg, N; Lehmann, P; Livingstone, E; Löffler, H; Loquai, C; Mauch, C; Mangana, J; Meier, F; Meissner, M; Moritz, RKC; Maul, LV; Müller, V; Mohr, P; Navarini, A; Van Nguyen, A; Pfeiffer, C; Pföhler, C; Posch, C; Richtig, E; Rompel, R; Sachse, MM; Sauder, S; Schadendorf, D; Schatton, K; Schulze, HJ; Schultz, E; Schilling, B; Schmuth, M; Simon, JC; Streit, M; Terheyden, P; Thiem, A; Tüting, T; Welzel, J; Weyandt, G; Wesselmann, U; Wollina, U; Ziemer, M; Zimmer, L; Zutt, M; Berking, C; Schlaak, M; Heppt, MV; German Dermatologic Cooperative Oncology Group (DeCOG, committee ocular melanoma) Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG).
J Cancer Res Clin Oncol. 2021; 147(6):1763-1771 Doi: 10.1007/s00432-020-03450-0 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** van Akkooi, ACJ; Haferkamp, S; Papa, S; Franke, V; Pinter, A; Weishaupt, C; Huber, MA; Loquai, C; Richtig, E; Gokani, P; Öhrling, K; Louie, KS; Mohr, P A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB-IVM1a Melanoma in Four European Countries.
Adv Ther. 2021; Doi: 10.1007/s12325-020-01590-w [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** Wagner, NB; Lenders, MM; Kühl, K; Reinhardt, L; André, F; Dudda, M; Ring, N; Ebel, C; Stäger, R; Zellweger, C; Lang, R; Paar, M; Gussek, P; Richtig, G; Stürmer, SH; Kimeswenger, S; Oellinger, A; Forschner, A; Leiter, U; Weide, B; Gassenmaier, M; Schraag, A; Klumpp, B; Hoetzenecker, W; Berking, C; Richtig, E; Ziemer, M; Mangana, J; Terheyden, P; Loquai, C; Nguyen, VA; Gebhardt, C; Meier, F; Diem, S; Cozzio, A; Flatz, L; Röcken, M; Garbe, C; Eigentler, TK Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study.
J Immunother Cancer. 2021; 9(5): e002350 Doi: 10.1136/jitc-2021-002350 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** Werner, F; Wagner, C; Simon, M; Glatz, K; Mertz, KD; Laubli, H; Richtig, E; Griss, J; Wagner, SN Loss of Lymphotoxin Alpha-Expressing Memory B Cells Correlates with Metastasis of Human Primary Melanoma
DIAGNOSTICS. 2021; 11(7): 1238 Doi: 10.3390/diagnostics11071238 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Short report/Letter

** COVID Surg Collaborative Impact of Bacillus Calmette-Guérin (BCG) vaccination on postoperative mortality in patients with perioperative SARS-CoV-2 infection.
BJS OPEN. 2021; 5(6): Doi: 10.1093/bjsopen/zrab131 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** Richtig, G; Cerroni, L; Schmidt, H; Beham-Schmid, C; Deinlein, T; Vallant, C; Richtig, E Talimogene laherparepvec can initiate plasma cell invasion into infiltrated melanoma lesions - a case series.
J Eur Acad Dermatol Venereol. 2021; 35(3):e209-e211 Doi: 10.1111/jdv.16922
Web of Science PubMed FullText FullText_MUG

Abstract (Journal)

** Chen, MY; Werner, F; Wagner, C; Simon, M; Richtig, E; Mertz, KD; Griss, J; Wagner, SN Subtyping for B cell- and antibody secreting cell-subsets in human melanoma reveals age-, metastasis- and tumor stage-associated changes
EUR J IMMUNOL. 2021; 51: 372-372.
Web of Science

** Codo, P; Eigentler, T; Heinzerling, L; Krauss, J; Weishaupt, C; Ochsenreither, S; Lebbe, C; Mohr, P; Oliva, M; Oberoi, H; Terheyden, P; Perez, JT; Bauernfeind, FG; Fluck, M; Richtig, E; Soria, A; Gonzalez, M; Funkner, F; Wengenmayer, P; Vahrenhorst, D; Seibel, T; Quintini, G; Schmitt-Bormann, B; Scheel, B; Falk, M; Gnad-Vogt, U IMMUNE PROFILING OF PATIENTS WITH ADVANCED SOLID TUMORS TREATED WITH INTRATUMORALLY ADMINISTERED CV8102 AS A SINGLE-AGENT OR IN COMBINATION WITH ANTI-PD-1 ANTIBODIES IN PHASE I CLINICAL TRIAL
J IMMUNOTHER CANCER. 2021; 9: A502-A502. Doi: 10.1136/jitc-2021-SITC2021.473
Web of Science FullText FullText_MUG

** Richtig, E; Gutzmer, R; Loquai, C; Utikal, JS; Holler, C; Stadler, R; Forschner, A; Hassel, JC; Debus, D; Goppner, D; Fluck, M; Haferkamp, S; Kaatz, M; Welslau, M; Dummer, R; von Moos, R; Schmidt, A; Milde, L; Michielin, O; Schadendorf, D Encorafenib plus Binimetinib in Patients with locally advanced, non-resectable or metastatic BRAF(V600) mutated Melanoma: first Data from the multicenter, multinational, prospective, non-interventional Longitudinal Study BERING(MELANOMA)
J DTSCH DERMATOL GES. 2021; 19: 53-53. [Oral Communication]
Web of Science

** Siozopoulou, V; Khmelevskiy, A; Rodlauer-Kriegl, A; de Caluwe, T; Churov, A; Valyaeva, A; De Bruyen, L; Wener, R; Specenier, P; Cuvelier, C; Thienpont, M; Richtig, E; Pauwels, P Using real-world evidence data and machine learning to identify molecular biomarkers for patient response to immune checkpoint inhibitors in metastatic melanoma
ANN ONCOL. 2021; 32: S1383-S1383. Doi: 10.1016/j.annonc.2021.10.040 [Poster]
Web of Science FullText FullText_MUG

** Terbuch, A; Absenger, G; Steinlechner, S; Jost, P; Wurm, R; Wohlkonig, C; Olschewski, H; Richtig, E; Koch, L; Winder, T; Woll, E; Gerger, A Autriche - AUsTrian Registry for Immune CHEckpoint inhibitors
ONCOL RES TREAT. 2021; 44: 229-229. [Poster]
Web of Science

** Wagner, NB; Lenders, MM; Meier, F; Gebhardt, C; Loquai, C; Richtig, E; Rocken, M; Eigentler, TK Site-Specific Tumor Response and Impact on Therapy Outcomes in Advanced Melanoma Patients
J INVEST DERMATOL. 2021; 141(10):S196-S196. [Oral Communication]
Web of Science

** Zager, JS; Orloff, M; Ferrucci, PF; Glazer, ES; Ejaz, A; Richtig, E; Ochsenreither, S; Lowe, MC; Reddy, SA; Beasley, G; Gesierich, A; Dummer, R; Arance, AM; Fenwick, SW; Wheater, M; Ottensmeier, C Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases: Preliminary results of FOCUS (PHP-OCM-301/301A) phase III trial.
J CLIN ONCOL. 2021; 39(15): Doi: 10.1200/JCO.2021.39.15_suppl.9510 [Poster]
Web of Science FullText FullText_MUG

2020

Full paper/article (Journal)

** Dummer, R; Lebbé, C; Atkinson, V; Mandalà, M; Nathan, PD; Arance, A; Richtig, E; Yamazaki, N; Robert, C; Schadendorf, D; Tawbi, HA; Ascierto, PA; Ribas, A; Flaherty, KT; Pakhle, N; Campbell, CD; Gusenleitner, D; Masood, A; Brase, JC; Gasal, E; Long, GV Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.
Nat Med. 2020; 26(10): 1557-1563. Doi: 10.1038/s41591-020-1082-2
Web of Science PubMed FullText FullText_MUG

** Richtig, G; Richtig, E; Neiss, AN; Quehenberger, F; Gmainer, DG; Kamolz, LP; Lumenta, DB Does the time interval between sentinel lymph node biopsy and completion lymph node dissection affect outcome in malignant melanoma? A retrospective cohort study.
Int J Surg. 2020; 75:160-164 Doi: 10.1016/j.ijsu.2020.01.146
Web of Science PubMed FullText FullText_MUG

** Theiler-Schwetz, V; Trummer, C; Richtig, E; Richtig, G; Pilz, S Thyroid disorders during immune checkpoint inhibitor therapy.
AUST J CLIN ENDOCR M. 2020; Doi: 10.1007/s41969-020-00111-y [OPEN ACCESS]
Web of Science FullText FullText_MUG

Review

** Richtig, E The therapeutic landscape of advanced melanoma.
MEMO-MAG EUR MED ONC. 2020; Doi: 10.1007/s12254-020-00593-1 [OPEN ACCESS]
Web of Science FullText FullText_MUG

Editorial

** Koelblinger, P; Nguyen, VA; Hoeller, C; Richtig, E Einfluss der Covid-19-Pandemie auf die dermatoonkologische Versorgung in Österreich.
J Dtsch Dermatol Ges. 2020; 18(7): 778-779. Doi: 10.1111/ddg.14137_g [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Abstract (Journal)

** Berger, M; Thueringer, A; Franz, D; Dandachi, N; Talakic, E; Richtig, G; Richtig, E; Rohrer, P; Koch, L; Wolf, I; Koch, C; Rainer, B; Koeller, M; Pichler, M; Kashofer, K; Aigelsreiter, A Feasibility and first results of circulating tumor DNA as a marker for treatment response in metastatic melanoma patients using Next Generation Sequencing.
ONCOL RES TREAT. 2020; 43(SUPPL 4):166-167. [Onlinepräsentation]
Web of Science

** Dummer, R; Biette, K; Gusenleitner, D; Ramesh, R; Lebbe, C; Atkinson, V; Mandala, M; Nathan, PD; Arance, A; Richtig, E; Yamazaki, N; Robert, C; Schadendorf, D; Tawbi, HAH; Ascierto, PA; Ribas, A; Flaherty, K; Gasal, E; Brase, JC; Long, GV Effect of first-line spartalizumab plus dabrafenib plus trametinib on immunosuppressive features detected in peripheral blood and clinical outcome in patients (pts) with advanced BRAF V600-mutant melanoma.
J CLIN ONCOL. 2020; 38(15):-ASCO 2020; May 29-31, 2020; Chicago. [Poster]
Web of Science

** Dummer, R; Gusenleitner, D; Campbell, CD; Lebbe, C; Atkinson, V; Mandala, M; Nathan, PD; Arance, A; Richtig, E; Yamazaki, N; Robert, C; Schadendorf, D; Tawbi, HAH; Ascierto, PA; Ribas, A; Flaherty, K; Gasal, E; Brase, JC; Long, GV Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600-mutant melanoma treated with first-line spartalizumab (S) plus dabrafenib (D) plus trametinib (T).
J CLIN ONCOL. 2020; 38(5):-ASCO-SITC Clinical Immuno-Oncology Symposium; FEB 06-08, 2020; Orlando, FL. [Poster]
Web of Science

** Long, GV; Lebbe, C; Atkinson, V; Mandala, M; Nathan, PD; Arance, A; Richtig, E; Yamazaki, N; Robert, C; Schadendorf, D; Tawbi, HAH; Ascierto, PA; Ribas, A; Flaherty, K; Lee, DY; Masood, A; Gasal, E; Dummer, R The anti-PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-I.
J CLIN ONCOL. 2020; 38(5):-ASCO-SITC Clinical Immuno-Oncology Symposium; FEB 06-08, 2020; Orlando, FL. [Poster]
Web of Science

** Long, GV; Lebbe, C; Atkinson, V; Mandala, M; Nathan, PD; Arance, A; Richtig, E; Yamazaki, N; Robert, C; Schadendorf, D; Tawbi, HAH; Ascierto, PA; Ribas, A; Flaherty, K; Pakhle, N; Masood, A; Gasal, E; Dummer, R The anti-PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600-mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial.
J CLIN ONCOL. 2020; 38(15):-ASCO 2020; May 29-31, 2020.; Chicago. [Poster]
Web of Science

** Richtig, E; Debus, D; Stadler, R; Holler, C; Utikal, JS; Dummer, R; Haferkamp, S; von Moos, R; Michielin, O; Schadendorf, D Encorafenib plus Binimetinib in Patients with locally advanced, inoperable, or metastatic BRAFV600 mutated Melanoma: First Data from the multicenter, multinational, prospective, non-interventional Longitudinal Study BERINGMELANOM.
J DTSCH DERMATOL GES. 2020; 18: 81-82.-ADO; September 9-12, 2020.; Ludwigshafen. [Oral Communication]
Web of Science

2019

Full paper/article (Journal)

** Emran, AA; Marzese, DM; Menon, DR; Hammerlindl, H; Ahmed, F; Richtig, E; Duijf, P; Hoon, DS; Schaider, H Commonly integrated epigenetic modifications of differentially expressed genes lead to adaptive resistance in cancer.
EPIGENOMICS-UK. 2019; 11(7): 732-737. Doi: 10.2217/epi-2018-0173 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** Müller, C; Wendt, J; Rauscher, S; Sunder-Plassmann, R; Richtig, E; Fae, I; Fischer, G; Okamoto, I Risk Factors of Subsequent Primary Melanomas in Austria.
JAMA Dermatol. 2019; 155(2):188-195 Doi: 10.1001/jamadermatol.2018.4645 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** Richtig, G; Richtig, E; Böhm, A; Oing, C; Bozorgmehr, F; Kruger, S; Kiesewetter, B; Zielinski, C; Berghoff, AS Awareness of predatory journals and open access among medical oncologists: results of an online survey.
ESMO Open. 2019; 4(6): e000580-e000580. Doi: 10.1136/esmoopen-2019-000580 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** Richtig, G; Richtig, M; Hoetzenecker, W; Saxinger, W; Lange-Asschenfeldt, B; Steiner, A; Strohal, R; Posch, C; Bauer, JW; Müllegger, RR; Deinlein, T; Sepp, N; Volc-Platzer, B; Nguyen, VA; Schmuth, M; Hoeller, C; Pregartner, G; Richtig, E Knowledge and Influence of Predatory Journals in Dermatology: A Pan-Austrian Survey.
Acta Derm Venereol. 2019; 99(1):58-62 Doi: 10.2340/00015555-3037 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Short report/Letter

** Richtig, G; Ramelyte, E; Koch, L; Greinix, H; Ferrone, S; Dummer, R; Richtig, E Unmasking of a primary desmoplastic melanoma tumour in the course of treatment of a metastatic disease with anti-PD-1 monoclonal antibody.
J Eur Acad Dermatol Venereol. 2019; 33(10):e381-e383-e381-e383 Doi: 10.1111/jdv.15675 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Abstract (Journal)

** Dummer, R; Gusenleitner, D; Campbell, CD; Lebbe, C; Atkinson, V; Mandala, M; Nathan, PD; Arance, A; Richtig, E; Yamazaki, N; Robert, C; Schadendorf, D; Tawbi, HAH; Ascierto, PA; Ribas, A; Flaherty, K; Gasal, E; Brase, JC; Long, GV Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600-mutant melanoma treated with first-line spartalizumab (S) plus dabrafenib (D) plus trametinib (T).
J CLIN ONCOL. 2019; 37(15): Doi: 10.1200/JCO.2019.37.15_suppl.9515 [Poster]
Web of Science FullText FullText_MUG

** Hoeller, C; Ressler, JM; Karasek, M; Lopez, VA; Koch, L; Kehrer, H; Koelblinger, P; Weihsengruber, F; Kofler, J; Richtig, E; Michielin, OA; Hafner, C Real life use of talimogene laherparepvec in melanoma in centers in Austria and Switzerland
ANN ONCOL. 2019; 30: 548-+.-44th Congress of the European-Society-for-Medical-Oncology (ESMO); SEP 27-OCT 01, 2019; Barcelona, SPAIN. [Poster]
Web of Science

** Long, GV; Lebbe, C; Atkinson, V; Mandala, M; Nathan, PD; Fernandez, ANAMA; Richtig, E; Yamazaki, N; Robert, C; Schadendorf, D; Tawbi, HAH; Ascierto, PA; Ribas, A; Flaherty, K; Lee, DY; Masood, A; Gasal, E; Dummer, R The anti-PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAFV600-mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i.
J CLIN ONCOL. 2019; 37(15): Doi: 10.1200/JCO.2019.37.15_suppl.9531 [Poster]
Web of Science FullText FullText_MUG

** Schadendorf, D; Haferkamp, S; Richtig, E; Holler, C Encorafenib and Binimetinib Combination in Patients with locally advanced, inoperable or metastatic BRAF(V600) mutant Melanoma: A multi-centre, multinational, prospective, non-interventional Longitudinal Study in Germany and Austria - BERING(MELANOM).
J DTSCH DERMATOL GES. 2019; 17: 75-75.-29. Deutschen Hautkrebskongresses (ADO–Jahrestagung) ; September 11-14; 2019; Ludwigshafen. [Poster]
Web of Science

2018

Full paper/article (Journal)

** Carlino, MS; Long, GV; Schadendorf, D; Robert, C; Ribas, A; Richtig, E; Nyakas, M; Caglevic, C; Tarhini, A; Blank, C; Hoeller, C; Bar-Sela, G; Barrow, C; Wolter, P; Zhou, H; Emancipator, K; Jensen, EH; Ebbinghaus, S; Ibrahim, N; Daud, A Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.
EUR J CANCER. 2018; 101(3): 236-243. Doi: 10.1016/j.ejca.2018.06.034 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** Richtig, G; Hoeller, C; Wolf, M; Wolf, I; Rainer, BM; Schulter, G; Richtig, M; Grübler, MR; Gappmayer, A; Haidn, T; Kofler, J; Huegel, R; Lange-Asschenfeldt, B; Pichler, M; Pilz, S; Heinemann, A; Richtig, E Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study.
PLoS One. 2018; 13(10):e0204729-e0204729 Doi: 10.1371/journal.pone.0204729 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Short report/Letter

** Schatz, O; Zalaudek, I; Ghaffari, Tabrizi-Wizsy, N; Grechenig, C; Grinninger, P; Haas, A; Haybaeck, J; Hofmann-Wellenhof, R; Juch, H; Krassnig, S; Richtig, E; Lackner, A; Schwab, K; Wedrich, A; Weger, M; Schwab, C Melanocytes, Organogenesis, and Angiogenesis: Evidence for More than a Pigment-Producing Capability of Melanocytes.
Cells Tissues Organs. 2018; 206(1-2):6-8 Doi: 10.1159/000495908
Web of Science PubMed FullText FullText_MUG

Review

** Berger, M; Richtig, G; Kashofer, K; Aigelsreiter, A; Richtig, E The window of opportunities for targeted therapy in BRAFwt/NRASwt/KITwt melanoma: biology and clinical implications of fusion proteins and other mutations.
G Ital Dermatol Venereol. 2018; 153(3): 349-360. Doi: 10.23736/S0392-0488.18.05970-9 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** Richtig, E ASCO Congress 2018: melanoma treatment.
Memo. 2018; 11(4):261-265 Doi: 10.1007/s12254-018-0455-4 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** Richtig, G; Berger, M; Lange-Asschenfeldt, B; Aberer, W; Richtig, E Problems and challenges of predatory journals.
J Eur Acad Dermatol Venereol. 2018; 32(9): 1441-1449. Doi: 10.1111/jdv.15039 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Case Report

** Menzer, C; Beedgen, B; Rom, J; Duffert, CM; Volckmar, AL; Sedlaczek, O; Richtig, E; Enk, A; Jäger, D; Hassel, JC Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancy.
Eur J Cancer. 2018; 104(2):239-242 Doi: 10.1016/j.ejca.2018.09.008 (- Case Report)
Web of Science PubMed FullText FullText_MUG

Abstract (Journal)

** Dummer, R; Schadendorf, D; Nathan, P; Tawbi, H; Robert, C; Ascierto, PA; Ribas, A; Lebbe, C; Mandala, M; Yamazaki, N; Richtig, E; Miller, WH; Gasal, E; Kaper, M; Brase, JC; Mookerjee, B; Long, GV The anti-PD-1 antibody spartalizumab (PDR001) in combination with dabrafenib and trametinib in previously untreated patients with advanced BRAF V600-mutant melanoma: First efficacy, safety, and biomarker findings from the part 2 biomarker cohort of COMBi-i
CANCER RES. 2018; 78(13):-Annual Meeting of the American-Association-for-Cancer-Research (AACR); APR 14-18, 2018; Chicago, IL. Doi: 10.1158/1538-7445.AM2018-CT182 [Oral Communication]
Web of Science FullText FullText_MUG

** Homicsko, K; Richtig, G; Tuchmann, F; Tsourti, Z; Hanahan, D; Coukos, G; Wind-Rotolo, M; Richtig, E; Zygoura, P; Holler, C; Dafni, U; Michielin, OA Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients
ANN ONCOL. 2018; 29: 40-40.-ESMO Immuno-Oncology Congress; DEC 13-16, 2018; Geneva, SWITZERLAND. [Oral Communication]
Web of Science FullText

** Koeller, M; Berger, M; Eder, S; Richtig, G; Richtig, E; Pichler, M; Winter, G; Hoefler, G; Aigelsreiter, A. Is microsatellite-instability a prognostic factor in melanoma patients treated with immune-checkpoint inhibitors?
VIRCHOWS ARCH. 2018; 473: S9-S10. [Oral Communication]
Web of Science

2017

Full paper/article (Journal)

** Deinlein, T; Wolf, IH; Rainer, B; Kupsa, R; Richtig, E; Hofmann-Wellenhof, R; Zalaudek, I Treatment of Primary and Metastatic Multifocal Mucosal Melanoma of the Oral Cavity with Imatinib.
Case Rep Oncol. 2017; 10(2):558-563 Doi: 10.1159/000477563 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** Petrella, TM; Robert, C; Richtig, E; Miller, WH; Masucci, GV; Walpole, E; Lebbe, C; Steven, N; Middleton, MR; Hille, D; Zhou, W; Ibrahim, N; Cebon, J Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
EUR J CANCER. 2017; 86(5): 115-124. Doi: 10.1016/j.ejca.2017.08.032 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** Schwab, C; Mayer, C; Zalaudek, I; Riedl, R; Richtig, M; Wackernagel, W; Hofmann-Wellenhof, R; Richtig, G; Langmann, G; Tarmann, L; Wedrich, A; Richtig, E Iris Freckles a Potential Biomarker for Chronic Sun Damage.
Invest Ophthalmol Vis Sci. 2017; 58(6):BIO174-BIO179 Doi: 10.1167/iovs.17-21751
Web of Science PubMed FullText FullText_MUG

** Ugurel, S; Loquai, C; Terheyden, P; Schadendorf, D; Richtig, E; Utikal, J; Gutzmer, R; Rass, K; Sunderkotter, C; Stein, A; Fluck, M; Kaatz, M; Trefzer, U; Kahler, K; Stadler, R; Berking, C; Holler, C; Kerschke, L; Edler, L; Kopp-Schneider, A; Becker, JC Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial
ONCOTARGET. 2017; 8(44): 76029-76043. Doi: 10.18632/oncotarget.18635 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Short report/Letter

** Gülseren, D; Arzberger, E; Cerroni, L; Hofmann-Wellenhof, R; Richtig, E Reflectance confocal microscopy and dermatopathologic findings of cutaneous argyria after colloidal silver ingestion.
J Eur Acad Dermatol Venereol. 2017; 31(3):e178-e179-e178-e179 Doi: 10.1111/jdv.13881
Web of Science PubMed FullText FullText_MUG

** Richtig, G; Richtig, E; Kashofer, K; Koch, L; Winter, G; Hoefler, G; Pichler, M; Ehall, B; Grübler, MR; Heinemann, A; Aigelsreiter, A Testing and clinical implications for non-V600 BRAF mutations in metastatic NRAS^mt melanoma.
Br J Dermatol. 2017; 177(3):860-861 Doi: 10.1111/bjd.15222
Web of Science PubMed FullText FullText_MUG

Review

** Richtig, G; Ehall, B; Richtig, E; Aigelsreiter, A; Gutschner, T; Pichler, M Function and Clinical Implications of Long Non-Coding RNAs in Melanoma.
Int J Mol Sci. 2017; 18(4): Doi: 10.3390/ijms18040715 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** Richtig, G; Hoeller, C; Kashofer, K; Aigelsreiter, A; Heinemann, A; Kwong, LN; Pichler, M; Richtig, E Beyond the BRAF^V^600E hotspot: biology and clinical implications of rare BRAF gene mutations in melanoma patients.
Br J Dermatol. 2017; 177(4):936-944 Doi: 10.1111/bjd.15436
Web of Science PubMed FullText FullText_MUG

Abstract (Journal)

** Long, GV; Blank, C; Ribas, A; Mortier, L; Carlino, MS; Lotem, M; Lorigan, P; Neyns, B; Petrella, TM; Puzanov, I; Richtig, E; O'Day, SJ; Masucci, G; Lebbe, C; Steven, N; Lutzky, J; Hille, D; Ebbinghaus, S; Ibrahim, N; McNeil, C Impact of baseline serum lactate dehydrogenase concentration on the efficacy of pembrolizumab and ipilimumab in patients with advanced melanoma: data from KEYNOTE-006
EUR J CANCER. 2017; 72: S122-S123.-ECCO European Cancer Congress; JAN 27-30, 2017; Amsterdam, NETHERLANDS. Doi: 10.1016/S0959-8049(17)30482-3 [Poster]
Web of Science FullText FullText_MUG

** Richtig, G; Byrom, L; Kupsa, R; Schaider, H; Hofmann-Wellenhof, R; Wolf, IH; Soyer, HP; Richtig, E Pregnancy as a driver for melanoma.
Br J Dermatol. 2017; 177(3):854-857 Doi: 10.1111/bjd.15124 (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

2016

Full paper/article (Journal)

** Eigentler, TK; Gutzmer, R; Hauschild, A; Heinzerling, L; Schadendorf, D; Nashan, D; Hölzle, E; Kiecker, F; Becker, J; Sunderkötter, C; Moll, I; Richtig, E; Pönitzsch, I; Pehamberger, H; Kaufmann, R; Pföhler, C; Vogt, T; Berking, C; Praxmarer, M; Garbe, C; Dermatologic Cooperative Oncology Group (DeCOG) Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial.
Ann Oncol. 2016; 27(8):1625-1632 Doi: 10.1093/annonc/mdw225 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** Hügel, R; Muendlein, A; Volbeding, L; Drexel, H; Richtig, E; Wehkamp, U; Painsi, C; Lange-Asschenfeldt, B; Hauschild, A; Egberts, F Serum levels of hepatocyte growth factor as a potential tumor marker in patients with malignant melanoma.
Melanoma Res. 2016; 26(4):354-360 Doi: 10.1097/CMR.0000000000000269
Web of Science PubMed FullText FullText_MUG

** Müller, C; Wendt, J; Rauscher, S; Burgstaller-Muehlbacher, S; Sunder-Plassmann, R; Scheurecker, C; Richtig, E; Fae, I; Fischer, G; Pehamberger, H; Okamoto, I Characterization of patients at high risk of melanoma in Austria.
BRIT J DERMATOL. 2016; 174(6): 1308-1317. Doi: 10.1111/bjd.14407
Web of Science PubMed FullText FullText_MUG

** Schwab, C; Wackernagel, W; Grinninger, P; Mayer, C; Schwab, K; Langmann, G; Richtig, E; Wedrich, A; Hofmann-Wellenhof, R; Zalaudek, I A Unifying Concept of Uveal Pigment Cell Distribution and Dissemination Based on an Animal Model: Insights into Ocular Melanogenesis.
Cells Tissues Organs. 2016; 201(3):232-8 Doi: 10.1159/000443877
Web of Science PubMed FullText FullText_MUG

** Trapp, EM; Trapp, M; Avian, A; Rohrer, PM; Weissenböck, T; Kapfhammer, HP; Demel, U; Linder, MD; Kresse, A; Richtig, E Association of Stress Coping Strategies with Immunological Parameters in Melanoma Patients.
ACTA DERM-VENEREOL. 2016; 96(217): 74-77. Doi: 10.2340/00015555-2372 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Short report/Letter

** Richtig, E; Asslaber, M; Partl, R; Avian, A; Berghold, A; Kapp, K; Preusser, M; Becker, JC; Curiel-Lewandrowski, C Lack of P-glycoprotein expression in melanoma brain metastases of different melanoma types.
CLIN NEUROPATHOL. 2016; 35(2): 89-92. Doi: 10.5414/NP300903
Web of Science PubMed FullText FullText_MUG

Review

** Richtig, E; Trapp, M; Kapfhammer, HP; Jenull, B; Richtig, G; Trapp, EM The Importance of a Biopsychosocial Approach in Melanoma ResearchExperiences from a Single-center Multidisciplinary Melanoma Working Group in Middle-Europe.
Acta Derm Venereol. 2016; 96(217):51-54 Doi: 10.2340/00015555-2426 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Case Report

** Richtig, G; Aigelsreiter, A; Kashofer, K; Talakic, E; Kupsa, R; Schaider, H; Richtig, E Two Case Reports of Rare BRAF Mutations in Exon 11 and Exon 15 with Discussion of Potential Treatment Options.
Case Rep Oncol. 2016; 9(3):543-546 Doi: 10.1159/000449125 (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Abstract (Journal)

** Blank, C; Ma, J; Grob, JJ; Larkin, J; Neyns, B; McNeil, C; Lotem, M; Richtig, E; Masucci, G; Petrella, T; Ribas, A; Wang, J; Ibrahim, N; Anderson, KM; Arance, A Estimating the percentage of patients with advanced melanoma achieving long-term survival with pembrolizumab (Pembro) treatment in KEYNOTE-006
ANN ONCOL. 2016; 27: Doi: 10.1093/annonc/mdw379.10
Web of Science FullText FullText_MUG

** Richtig, G; Ehall, B; Koch, L; Richtig, E; Winter, G; Eder, S; Kashofer, K; Heinemann, A; Hoefler, G; Aigelsreiter, A The clinical relevance of testing for non-V600E BRAF mutations in melanoma-a single center experience
VIRCHOWS ARCH. 2016; 469: S309-S309. [Oral Communication]
Web of Science

** Riding, G; Ehall, B; Koch, L; Richtig, E; Winter, G; Eder, S; Kashofer, K; Heinemann, A; Hoefler, G; Aigelsreiter, A The relevance of BRAF exon 11 testing in melanoma-single center experience
VIRCHOWS ARCH. 2016; 469: S193-S193. [Poster]
Web of Science

2015

Full paper/article (Journal)

** Macpherson, M; Hofmann-Wellenhof, R; Wiednig, M; Richtig, E; Zalaudek, I The importance of the given history in the differential diagnosis of blue nodules.
J Am Acad Dermatol. 2015; 72(5):e117-e118 Doi: 10.1016/j.jaad.2015.01.042 (- Case Report)
Web of Science PubMed FullText FullText_MUG

** Richtig, E; Arzberger, E; Hofmann-Wellenhof, R; Fink-Puches, R Assessment of changes in lentigo maligna during radiotherapy by in-vivo reflectance confocal microscopy: a pilot study.
Br J Dermatol. 2015; 172(1):81-87 Doi: 10.1111/bjd.13141
Web of Science PubMed FullText FullText_MUG

** Richtig, E; Trapp, EM; Avian, A; Brezinsek, HP; Trapp, M; Egger, JW; Kapfhammer, HP; Rohrer, PM; Berghold, A; Curiel-Lewandrowski, C; Demel, U Psychological Stress and Immunological Modulations in Early-stage Melanoma Patients.
Acta Derm Venereol. 2015; 95(6):691-695 Doi: 10.2340/00015555-2045 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** Robert, C; Schachter, J; Long, GV; Arance, A; Grob, JJ; Mortier, L; Daud, A; Carlino, MS; McNeil, C; Lotem, M; Larkin, J; Lorigan, P; Neyns, B; Blank, CU; Hamid, O; Mateus, C; Shapira-Frommer, R; Kosh, M; Zhou, H; Ibrahim, N; Ebbinghaus, S; Ribas, A; KEYNOTE-006 investigators Pembrolizumab versus Ipilimumab in Advanced Melanoma.
N Engl J Med. 2015; 372(26):2521-2532 Doi: 10.1056/NEJMoa1503093 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** Schwab, C; Zalaudek, I; Mayer, C; Riedl, R; Wackernagel, W; Juch, H; Aigner, B; Brunasso, AM; Langmann, G; Richtig, E New insights into oculodermal nevogenesis and proposal for a new iris nevus classification.
Br J Ophthalmol. 2015; 99(5):644-649 Doi: 10.1136/bjophthalmol-2014-305849
Web of Science PubMed FullText FullText_MUG

** Trapp, EM; Trapp, M; Sampogna, F; Rohrer, PM; Egger, JW; Wolf, P; Kapfhammer, HP; Linder, MD; Richtig, E; Baulmann, J; Hofer, A Autonomic nervous tone in vitiligo patients--a case-control study.
Acta Derm Venereol. 2015; 95(2):169-172 Doi: 10.2340/00015555-1896 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** Trapp, M; Egger, JW; Kapfhammer, HP; Trapp, EM; Rohrer, PM; Hörlesberger, N; Schwantzer, G; Komericki, P; Linder, MD; Lvov, A; Baulmann, J; Richtig, E Higher psychological and psychovegetative strain in adolescents with atypical pigment naevi.
Acta Derm Venereol. 2015; 95(1):67-71 Doi: 10.2340/00015555-1837 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Review

** Mössner, R; Zimmer, L; Berking, C; Hoeller, C; Loquai, C; Richtig, E; Kähler, KC; Hassel, JC; Gutzmer, R; Ugurel, S Erythema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature.
J Eur Acad Dermatol Venereol. 2015; 29(9):1797-1806 Doi: 10.1111/jdv.13039 (- Case Report)
Web of Science PubMed FullText FullText_MUG

Abstract (Journal)

** Middleton, M; Dalle, S; Corrie, P; Loquai, C; Terheyden, P; Kahler, KC; Meiss, F; Board, R; Arance, AM; Gutzmer, R; Tarhini, A; Dummer, R; Ernst, S; Richtig, E; Wolter, P; Bulger, K; Kotapati, S; Le, TK; Brokaw, J; Abernethy, AP Initial safety results from a multinational, prospective, observational study in advanced melanoma (MEL) (IMAGE).
EUR J CANCER. 2015; 51: S678-S679.-European Cancer Congress; Sept 25-29, 2015; Vienna, AUSTRIA. Doi: 10.1016/S0959-8049(16)31856-1 [Poster]
Web of Science FullText FullText_MUG

** Ugurel, S; Loquai, C; Terheyden, P; Schadendorf, D; Richtig, E; Utikal, J; Gutzmer, R; Rass, K; Sunderkotter, C; Stein, A; Fluck, M; Kaatz, M; Trefzer, U; Hauschild, A; Stadler, R; Berking, C; Pehamberger, H; Kopp-Schneider, A; Becker, JC Ex-vivo sensitivity-directed combination chemotherapy compared to DTIC monochemotherapy in chemo-naive advanced metastastic melanoma (ChemoSensMM): a multicenter randomized phase-3 DeCOG trial
J DTSCH DERMATOL GES. 2015; 13: 18-19.-25. Deutscher Hautkrebskongress; Sept 10-12, 2015; München. [Oral Communication]
Web of Science

2014

Full paper/article (Journal)

** Keeling, IM; Knez, I; Richtig, E; Zweiker, R; Aigelsreiter, A; Dacar, D Cardiac surgery for metastatic melanoma.
Wien Klin Wochenschr. 2014; 126(9-10):261-262 Doi: 10.1007/s00508-014-0518-4 (- Case Report)
Web of Science PubMed FullText FullText_MUG

** Richtig, G; Richtig, E; Massone, C; Hofmann-Wellenhof, R Analysis of clinical, dermoscopic and histopathological features of primary melanomas of patients with metastatic disease--a retrospective study at the Department of Dermatology, Medical University of Graz, 2000-2010.
J Eur Acad Dermatol Venereol. 2014; 28(12):1776-1781 Doi: 10.1111/jdv.12413
Web of Science PubMed FullText FullText_MUG

** Zalaudek, I; Schmid, K; Niederkorn, A; Fink-Puches, R; Richtig, E; Wolf, I; Hofmann-Wellenhof, R Proposal for a clinical-dermoscopic classification of scalp naevi.
Br J Dermatol. 2014; 170(5):1065-1072 Doi: 10.1111/bjd.12722
Web of Science PubMed FullText FullText_MUG

Short report/Letter

** Niederkorn, A; Wackernagel, W; Artl, M; Schwantzer, G; Aigner, B; Richtig, E Response of patients with metastatic uveal melanoma to combined treatment with fotemustine and sorafenib.
Acta Ophthalmol. 2014; 92(8):e696-e697 Doi: 10.1111/aos.12432 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Review

** Aigner, B; Bauernhofer, T; Petru, E; Niederkorn, A; Arzberger, EJ; Richtig, E Complete recovery of a wide local reaction by the use of dexrazoxane 72 hours after epirubicin extravasation: case report and review of the literature.
Dermatology. 2014; 229(4):288-292 Doi: 10.1159/000365391 (- Case Report)
Web of Science PubMed FullText FullText_MUG

Abstract (Journal)

** Partl, R; Richtig, E; Avian, A; Berghold, A; Kapp, KS; KPS/LDH-Index for Prognosis Assessment of Whole-Brain Radiotherapy in Female Patients with malignant Melanoma.
STRAHLENTHER ONKOL. 2014; 190(1):128-128.-30th OEGRO Annual Conference; SEP 20-21, 2013; Bregenz, AUSTRIA. [Poster]
Web of Science

2013

Full paper/article (Journal)

** Aigner, B; Richtig, E; Becker, JC; Lingitz, H; Niederkorn, RMA; Ugurel, S; Partial Response of Metastatic Mucosal Melanoma After Palliative Chemotherapy With Trofosfamide: A Case Report.
J Clin Oncol. 2013; 31(2):e31-e32 Doi: 10.1200/JCO.2012.44.2053 (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** Partl, R; Richtig, E; Avian, A; Berghold, A; Kapp, KS Karnofsky performance status and lactate dehydrogenase predict the benefit of palliative whole-brain irradiation in patients with advanced intra- and extracranial metastases from malignant melanoma.
Int J Radiat Oncol Biol Phys. 2013; 85(3):662-666 Doi: 10.1016/j.ijrobp.2012.06.009
Web of Science PubMed FullText FullText_MUG

Short report/Letter

** Richtig, E; Schrama, D; Ugurel, S; Fried, I; Niederkorn, A; Massone, C; Becker, JC BRAF mutation analysis of only one single metastatic lesion can restrict the treatment of melanoma - a case report.
Br J Dermatol. 2013; 168(2):428-430 Doi: 10.1111/j.1365-2133.2012.11121.x (- Case Report)
Web of Science PubMed FullText FullText_MUG

Abstract (Journal)

** Aigner, B; El-Shabrawi, L; Niederkorn, L; Richtig, E; Herpes zoster-like Melanoma Metastases under Vemurafenib Therapy.
J DTSCH DERMATOL GES. 2013; 11(9):933-933. [Oral Communication]
Web of Science

** Aigner, B; Richtig, E; Cutaneous Side Effects of conventional Chemotherapy and new Immune- or Inhibitortherapies in Dermato-Oncology.
J DTSCH DERMATOL GES. 2013; 11(9):912-912.-23. Hautkrebskongress; Sept, 26-28, 2013; Essen. [Oral Communication]
Web of Science

** Partl, R; Richtig, E; Avian, A; Berghold, A; Kapp, KS Advanced intra-and extracranial Metastases in malignant Melanoma: Can the Parameters of KPS and Serum LDH give therapeutic Decision making?
STRAHLENTHER ONKOL. . 2013; 189(2):181-181.-29th Annual Meeting of the Austrian-Society-of-Radiation-Oncology-Radiobiology-and-Medical-Radiophysics (OGRO); SEP 28-29, 2012; Gnunden, AUSTRIA. [Poster]
Web of Science

** Partl, R; Richtig E; Avian, A; Berghold, A; Kapp, KS Die Rolle von Karnofsky-Performance-Status und Serum-LDH als wertvolle prognostische Parameter bei Patienten mit zerebral metastasierten malignen Melanomen
Strahlentherapie und Onkologie; Journal of Radiation Oncology, Biology, Physics. 2013; 189(1):103-103.-DEGRO-Kongress; MAI 9-12; Berlin, DEUTSCHLAND. [Poster]
Web of Science

2012

Full paper/article (Journal)

** Frühauf, J; Leinweber, B; Fink-Puches, R; Ahlgrimm-Siess, V; Richtig, E; Wolf, IH; Niederkorn, A; Quehenberger, F; Hofmann-Wellenhof, R Patient acceptance and diagnostic utility of automated digital image analysis of pigmented skin lesions.
J Eur Acad Dermatol Venereol. 2012; 26(3):368-372 Doi: 10.1111/j.1468-3083.2011.04081.x
Web of Science PubMed FullText FullText_MUG

** Trapp, M; Trapp, EM; Richtig, E; Egger, JW; Zampetti, A; Sampogna, F; Rohrer, PM; Komericki, P; Strimitzer, T; Linder, MD Coping strategies in melanoma patients.
Acta Derm Venereol. 2012; 92(6):598-602 Doi: 10.2340/00015555-1351 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Short report/Letter

** Partl, R; Richtig, E; Kapp, KS Calling attention to radiation recall reactions. Simultaneous occurrence of a Recall Dermatitis after CMF application in two separate sites irradiated 10 years apart.
Acta Oncol. 2012; 51(6):809-811 Doi: 10.3109/0284186X.2011.639799 (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Abstract (Journal)

** Aigner, B; Richtig, E; Becker, J; Marterer, R; Niederkom, A; Lingitz, H; Ugurel, S; Partial Remission of metastatic Mucosal melanoma receiving palliative therapy with Trofosfamide.
J DTSCH DERMATOL GES. 2012; 10(9):695-695.-ADO; Hannover. [Poster]
Web of Science

** Niederkorn, A; Arzberger, E; Wurm, EMT; Richtig, E; Fink-Puches, R; Schaider, H; Wolf, IH; Hofmann-Wellenhof, R; Confocal: laser scanning microscopy, a useful complement in the diagnosis of regressive lesions?.
J DTSCH DERMATOL GES. 2012; 10(9):677-677. Doi: 10.1111/j.1610-0387.2012.08011.x [Oral Communication]
Web of Science FullText FullText_MUG

2011

Full paper/article (Journal)

** Koller, S; Wiltgen, M; Ahlgrimm-Siess, V; Weger, W; Hofmann-Wellenhof, R; Richtig, E; Smolle, J; Gerger, A In vivo reflectance confocal microscopy: automated diagnostic image analysis of melanocytic skin tumours.
J Eur Acad Dermatol Venereol. 2011; 25(5):554-558 Doi: 10.1111/j.1468-3083.2010.03834.x
Web of Science PubMed FullText FullText_MUG Google Scholar

** Richtig, E; Hofmann-Wellenhof, R; Kopera, D; El-Shabrawi-Caelen, L; Ahlgrimm-Siess, V In vivo analysis of solar lentigines by reflectance confocal microscopy before and after Q-switched ruby laser treatment.
Acta Derm Venereol. 2011; 91(2):164-168 Doi: 10.2340/00015555-1024 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Case Report

** Richtig, E; Ahlgrimm-Siess, V; Arzberger, E; Hofmann-Wellenhof, R Noninvasive differentiation between mamillary eczema and Paget disease by in vivo reflectance confocal microscopy on the basis of two case reports.
Br J Dermatol. 2011; 165(2):440-441 Doi: 10.1111/j.1365-2133.2011.10380.x (- Case Report)
Web of Science PubMed FullText FullText_MUG

Correspondence

** Richtig, E; Komericki, P; Zalaudek, I Response to the letter, "Underpowered conclusions can be potentially misleading with regards to the number of lymphoscintigraphy identified and surgically excised sentinel nodes in melanoma patients" by Nicholas C. Lee and Andrew J. Spillane.
Eur J Surg Oncol. 2011; 37(5): 456-457. Doi: 10.1016/j.ejso.2011.02.010
Web of Science PubMed FullText FullText_MUG

Abstract (Journal)

** Justich, A; Niederkorn, A; Tilz, H; Massone, C; Richtig, E; Becker, J; Ugurel, S Regression of a case of complete Paraplegia due to multiple Vertebral Body Metastases of a Melanoma being treated by BRAF-Inhibitor Vemurafenib
J DTSCH DERMATOL GES. 2011; 9(9):786-786.-21. Jahrestagung der ADO; Sept 15-17, 2011; Weimar, Deutschland. [Poster]
Web of Science

** Niederkorn, A; Tilz, HE; Justich, A; Richtig, E; Ugurel, S; Becker, J Response of an inoperative Relapse of a primary cutaneous large B-Cell-Lymphoma with endonasal Infiltration during Chemotherapy with pegylated liposomal Doxorubicine in Combination with Rituximab.
J DTSCH DERMATOL GES. 2011; 9(9):787-787.-21. Jahrestagung der ADO; Sept 15-17, 2011; Weimar, Deutschland. [Poster]
Web of Science

** Richtig, E; Ugurel, S; Niederkorn, A; Justich, A; Tilz, H; Becker, J Onset and rapid Progression of Vitiligo in a Patient with metastatic malignant Melanoma under Ipilimumag Therapy - possibly triggered by an increase in ACTH Process?
J DTSCH DERMATOL GES. 2011; 9(9):784-784.-21. Jahrestagung der ADO; Sept 15-17, 2011; Weimar, Deutschland. [Poster]
Web of Science

** Richtig, E; Ugurel, S; Niederkorn, A; Justich, A; Tilz, H; Becker, J Increase of Pancreatic Enzymes and of the Cortisol Levels in Patients with metastatic Melanoma under a Therapy with Ipilimumab
J DTSCH DERMATOL GES. 2011; 9(9):784-784.-21. Jahrestagung der ADO; Sept 15-17, 2011; Weimar, Deutschland. [Poster]
Web of Science

** Tilz, HE; Niederkorn, A; Justich, A; Prettenhofer, U; Massone, C; Richtig, E; Becker, J; Ugurel, S Successful Therapy of a Stewart Treves Angio Sarcoma by way of Radiation and Paclitaxel
J DTSCH DERMATOL GES. 2011; 9(9):789-789. [Poster]
Web of Science

2010

Full paper/article (Journal)

** Damm, S; Koefinger, P; Stefan, M; Wels, C; Mehes, G; Richtig, E; Kerl, H; Otte, M; Schaider, H HGF-promoted motility in primary human melanocytes depends on CD44v6 regulated via NF-kappa B, Egr-1, and C/EBP-beta.
J Invest Dermatol. 2010; 130(7): 1893-1903. Doi: 10.1038/jid.2010.45 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

** Richtig, E; Ahlgrimm-Siess, V; Koller, S; Gerger, A; Horn, M; Smolle, J; Hofmann-Wellenhof, R Follow-up of actinic keratoses after shave biopsy by in-vivo reflectance confocal microscopy--a pilot study.
J Eur Acad Dermatol Venereol. 2010; 24(3):293-298 Doi: 10.1111/j.1468-3083.2009.03410.x
Web of Science PubMed FullText FullText_MUG

** Richtig, E; Komericki, P; Trapp, M; Ott, A; Bisail, B; Egger, JW; Zalaudek, I Ratio of marked and excised sentinel lymph nodes and scintigraphic appearance time in melanoma patients with negative sentinel lymph node.
Eur J Surg Oncol. 2010; 36(8):783-788 Doi: 10.1016/j.ejso.2010.05.003
Web of Science PubMed FullText FullText_MUG

** Schintler, MV; Arbab, E; Laback, C; Prandl, E; Kash, N; Scharnagl, E; Richtig, E Neurofibroma of the tibial nerve mimicking popliteal lymph node metastasis in malignant melanoma.
Dermatol Surg. 2010; 36(4): 555-557. Doi: 10.1111/j.1524-4725.2010.01500.x (- Case Report)
Web of Science PubMed FullText FullText_MUG

Abstract (Journal)

** Linder, MD; Miggitsch, EM; Trapp, M; Richtig, E; Egger, JW Biopsychosocial research - skin conductance reactivity post stress and social orientation
J PSYCHOSOM RES. 2010; 68(6):100--XXVIII European Conference on Psychosomatic Research (ECPR) & XIII Annual Scientific Meeting European Association for Consultation-Liaison Psychiatry and Psychosomatics (EACLPP); June 30th July 3rd 2010 ; Innsbruck, Austria. [Poster]
Web of Science

** Tilz, H; Wolf, I; Weger, W; Massone, C; Richtig, E; Becker, JC Ulcus terebrans in two farmers
J DTSCH DERMATOL GES. 2010; 8(9): 756-756. [Poster]
Web of Science

2009

Full paper/article (Journal)

** Ahlgrimm-Siess, V; Massone, C; Scope, A; Fink-Puches, R; Richtig, E; Wolf, IH; Koller, S; Gerger, A; Smolle, J; Hofmann-Wellenhof, R Reflectance confocal microscopy of facial lentigo maligna and lentigo maligna melanoma: a preliminary study.
Br J Dermatol. 2009; 161(6):1307-1316 Doi: 10.1111/j.1365-2133.2009.09289.x
Web of Science PubMed FullText FullText_MUG Google Scholar

** Binder, B; Richtig, E; Weger, W; Ginter-Hanselmayer, G Tinea capitis in early infancy treated with itraconazole: a pilot study.
J Eur Acad Dermatol Venereol. 2009; 23(10): 1161-1163. Doi: 10.1111/j.1468-3083.2009.03271.x
Web of Science PubMed FullText FullText_MUG

** Hofmann-Wellenhof, R; Wurm, EM; Ahlgrimm-Siess, V; Richtig, E; Koller, S; Smolle, J; Gerger, A Reflectance confocal microscopy--state-of-art and research overview.
Semin Cutan Med Surg. 2009; 28(3):172-179 Doi: 10.1016/j.sder.2009.06.004
Web of Science PubMed FullText FullText_MUG Google Scholar

** Niederkorn, A; Ahlgrimm-Siess, V; Fink-Puches, R; Wolf, IH; Richtig, E; Lackner, HK; Hofmann-Wellenhof, R Frequency, clinical and dermoscopic features of benign papillomatous melanocytic naevi (Unna type).
Br J Dermatol. 2009; 161(3):510-514 Doi: 10.1111/j.1365-2133.2009.09239.x
Web of Science PubMed FullText FullText_MUG Google Scholar

** Richtig, E; Gerger, A; El-Shabrawi-Caelen, L; Szkandera, J; Hofmann-Wellenhof, R Reflectance confocal microscopy in early diagnosis of cutaneous metastases of breast cancer.
Gynecol Oncol. 2009; 115(3):510-511 Doi: 10.1016/j.ygyno.2009.08.030 (- Case Report)
Web of Science PubMed FullText FullText_MUG

** Richtig, E; Jung, E; Asbäck, K; Trapp, M; Hofmann-Wellenhof, R Knowledge and perception of melanocytic nevi and sunburn in young children.
Pediatr Dermatol. 2009; 26(5): 519-523. Doi: 10.1111/j.1525-1470.2008.00854.x
Web of Science PubMed FullText FullText_MUG Google Scholar

Abstract (Journal)

** Damm, S; Wels, C; Kofinger, P; Stefan, M; Mehes, G; Richtig, E; Kerl, H; Otte, M; Schaider, H Hepatocyte growth factor promotes motility in human melanocytes through CD44v6 via NF-kappa B.
EXP DERMATOL. 2009; 18(3):316-316.-ADF 2009; Maerz 5-7, 2009; Heidelberg, GERMANY. [Poster]
Web of Science

** Miggitsch, EM; Egger, JW; Trapp, M; Rohrer, PM; Richtig, E Stress-Coping in Patients with Malignant Melanoma.
Acta Dermato-Venerologica - International Journal for Skin Research, Clinical Dermatology and Sexually Transmitted Diseases. 2009; 89(5):585-586.-13th Congress of the European Society for Dermatology and Psychiatry ESDAP Acta Dermato-Venerologica 2009/89/5 - Print journal ISSN 0001-5555; Online content ISSN 1651-2057; SEPT 17-22, 2009; Venice, ITALY. [Poster]
Web of Science

** Miggitsch, EM; Trapp, M; Richtig, E; Rohrer, PM; Domej, W; Velik, R; Egger, JW Gender Specific Aspects of Skin Temperature-Reactivity Under Hypobaric Hypoxia.
Acta Dermato-Venerologica - International Journal for Skin Research, Clinical Dermatology and Sexually Transmitted Diseases. 2009; 89(5):586-586.-13th Congress of the European Society for Dermatology and Psychiatry - ESDAP Acta Dermato-Venerologica 2009/89/5 - Print journal ISSN 0001-5555; Online content ISSN 1651-2057; SEPT 17-22, 2009; Venice, ITALY. [Poster]
Web of Science

** Trapp, M; Egger, JW; Miggitsch, EM; Rohrer, PM; Schwaberger, G; Richtig, E Reactivity of Skin Conductance Variability and Social Isolation.
Acta Dermato-Venerologica - International Journal for Skin Research, Clinical Dermatology and Sexually Transmitted Diseases.2009; 89(5):591-591.-13th Congress of the European Society for Dermatology and Psychiatry ESDAP Acta Dermato-Venerologica 2009/89/5 - Print journal ISSN 0001-5555; Online content ISSN 1651-2057; SEPT 17-22, 2009; Venice, ITALY. [Poster]
Web of Science

Comment

** Richtig, E Reply.
Dermatology. 2009; 218(1): 89-89. Doi: 10.1159/000163084 [OPEN ACCESS]
Web of Science FullText FullText_MUG

2008

Full paper/article (Journal)

** Ahlgrimm-Siess, V; Massone, C; Koller, S; Fink-Puches, R; Richtig, E; Wolf, I; Gerger, A; Hofmann-Wellenhof, R In vivo confocal scanning laser microscopy of common naevi with globular, homogeneous and reticular pattern in dermoscopy.
Br J Dermatol. 2008; 158(5):1000-1007 Doi: 10.1111/j.1365-2133.2008.08460.x
Web of Science PubMed FullText FullText_MUG Google Scholar

** Gerger, A; Hofmann-Wellenhof, R; Langsenlehner, U; Richtig, E; Koller, S; Weger, W; Ahlgrimm-Siess, V; Horn, M; Samonigg, H; Smolle, J In vivo confocal laser scanning microscopy of melanocytic skin tumours: diagnostic applicability using unselected tumour images.
Br J Dermatol. 2008; 158(2):329-333 Doi: 10.1111/j.1365-2133.2007.08389.x
Web of Science PubMed FullText FullText_MUG Google Scholar

** Gerger, A; Wiltgen, M; Langsenlehner, U; Richtig, E; Horn, M; Weger, W; Ahlgrimm-Siess, V; Hofmann-Wellenhof, R; Samonigg, H; Smolle, J Diagnostic image analysis of malignant melanoma in in vivo confocal laser-scanning microscopy: a preliminary study
SKIN RES TECHNOL. 2008; 14(3): 359-363. Doi: 10.1111/j.1600-0846.2008.00303.x
Web of Science PubMed FullText FullText_MUG Google Scholar

** Richtig, E; Ambros-Rudolph, CM; Trapp, M; Lackner, HK; Hofmann-Wellenhof, R; Kerl, H; Schwaberger, G Melanoma markers in marathon runners: increase with sun exposure and physical strain.
Dermatology. 2008; 217(1): 38-44. Doi: 10.1159/000121473
Web of Science PubMed FullText FullText_MUG Google Scholar

** Richtig, E; Santigli, E; Fink-Puches, R; Weger, W; Hofmann-Wellenhof, R Assessing melanoma risk factors: how closely do patients and doctors agree?
Public Health. 2008; 122(12): 1433-1439. Doi: 10.1016/j.puhe.2008.04.012
Web of Science PubMed FullText FullText_MUG Google Scholar

Abstract (Journal)

** Richtig, E; Weger, W; Binder, B; Ginter-Hanselmayer, G Tinea capitis in newborns.
. 2008; 51: 387-388. [Oral Communication]
Web of Science

2007

Full paper/article (Journal)

** Richtig, E; Berghold, A; Schwantzer, G; Ott, A; Wölfelmaier, F; Karner, B; Ludwig, R; Denk, H; Stering, R; Leitner, G; Lax, S; Okcu, M; Gerger, A; Kerl, H; Smolle, J Clinical epidemiology of invasive cutaneous malignant melanoma in the Austrian province Styria in the years 2001-2003 and its relationship with local geographical, meteorological and economic data.
Dermatology. 2007; 214(3):246-252 Doi: 10.1159/000099590
Web of Science PubMed FullText FullText_MUG Google Scholar

** Richtig, E; Gerger, A; Berghold, A; Schwantzer, G; Ott, A; Kerl, H; Smolle, J Natural history of invasive cutaneous melanoma in Styria, Austria 2001-2003.
J Dtsch Dermatol Ges. 2007; 5(4): 293-299. Doi: 10.1111/j.1610-0387.2007.06246.x
PubMed FullText FullText_MUG Google Scholar

** Richtig, E; Zalaudek, I; Ahlgrimm-Siess, V; Leinweber, B; Hofmann-Wellenhof, R Repigmentation after surgery of melanoma in a burn scar: dermoscopy as aid for the management decision.
Dermatol Surg. 2007; 33(7): 839-841. Doi: 10.1111/j.1524-4725.2007.33179.x (- Case Report)
Web of Science PubMed FullText FullText_MUG Google Scholar

** Seidl, H; Richtig, E; Tilz, H; Stefan, M; Schmidbauer, U; Asslaber, M; Zatloukal, K; Herlyn, M; Schaider, H Profiles of chemokine receptors in melanocytic lesions: de novo expression of CXCR6 in melanoma.
Hum Pathol. 2007; 38(5):768-780 Doi: 10.1016/j.humpath.2006.11.013
Web of Science PubMed FullText FullText_MUG Google Scholar

Abstract (Journal)

** Gerger, A; Hofmann-Wellenhof, R; Langsenlehner, U; Koller, S; Weger, W; Richtig, E; Horn, M; Samonigg, H; Smolle, J In vivo confocal laser-scanning microscopy: bringing melanoma histopathology to the bedside.
J Invest Dermatol; 2007; 127(S2):S49-S49.-37 th Annual ESDR Meeting; SEP 5-8, 2007; Zürich, Switzerland. [Poster]
Web of Science

** Hofmann-Wellenhof, R; Ahlgrimm-Siess, V; Fink-Puches, R; Richtig, E; Wolf, IH; Gerger, A; Smolle, J; Kerl, H In vivo Confocal laser scanning microscopy of equivocal pigmented skin lesions
J INVEST DERMATOL. 2007; 127: S25-S25.-The 37th Meeting of the European Society for Dermatological Research (ESDR); 5-9 September 2007; Zürich. [Oral Communication]
Web of Science

** Horn, M; Gerger, A; Wiltgen, M; Langsenlehner, U; Hofmann-Wellenhof, R; Weger, W; Richtig, E; Samonigg, H; Smolle, J Diagnostic image analysis of malignant melanoma in in-vivo confocal laser-scanning microscopy.
J Invest Dermatol;2007; 127(S2):S91-S91.-37 th Annual ESDR Meeting; SEP 5-8, 2007; Zürich, Switzerland. [Poster]
Web of Science

** Quan, P; Richtig, E; Seidl, H; Stefan, M; Tilz, H; Asslaber, M; Schmidbauer, U; Zatloukal, K; Kerl, H; Schaider, H Expression profiles of chemokine receptors in melanoma metastases
EXP DERMATOL. 2007; 16(3):227-227. [Poster]
Web of Science

** Rottensteiner, M; Tamussino, K; Bader, A; Aigner, R; Schwarz, T; Regauer, S; Richtig, E; Lahousen, M; Winter, R The sentinel lymph node concept in vulvar cancer
GEBURTSH FRAUENHEILK. 2007; 67(5):502-502.-Gem.Tagung Bayerische Gesellschaft für Geburtshilfe und Frauenheilkunde und Österreichische Gesellschaft für Gynäkologie und Geburtshilfe; JUNE 7 - 9, 2007; München, Germany. [Poster]
Web of Science

2006

Full paper/article (Journal)

** Ambros-Rudolph, CM; Hofmann-Wellenhof, R; Richtig, E; Müller-Fürstner, M; Soyer, HP; Kerl, H Malignant melanoma in marathon runners.
Arch Dermatol. 2006; 142(11): 1471-1474. Doi: 10.1001/archderm.142.11.1471 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** Gerger, A; Koller, S; Weger, W; Richtig, E; Kerl, H; Samonigg, H; Krippl, P; Smolle, J Sensitivity and specificity of confocal laser-scanning microscopy for in vivo diagnosis of malignant skin tumors.
Cancer. 2006; 107(1): 193-200. Doi: 10.1002/cncr.21910 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Pressetext

** Hartmann, P; Mirtolouei, R; Untersberger, S; Ziegler, W; Hermann, Z; Richtig, E; Hofmann-Wellenhof, R; Grinschgl, S; Kerl, H; Smolle, J Non-invasive imaging of tissue PO2 in malignant melanoma of the skin.
Melanoma Res. 2006; 16(6): 479-486. Doi: 10.1097/01.cmr.0000222605.03675.1d
Web of Science PubMed FullText FullText_MUG Google Scholar

** Kolm, I; Di Stefani, A; Hofmann-Wellenhof, R; Fink-Puches, R; Wolf, IH; Richtig, E; Smolle, J; Kerl, H; Soyer, HP; Zalaudek, I Dermoscopy patterns of halo nevi.
Arch Dermatol. 2006; 142(12):1627-1632 Doi: 10.1001/archderm.142.12.1627 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** Richtig, E; Langmann, G; Schlemmer, G; Müllner, K; Papaefthymiou, G; Bergthaler, P; Smolle, J Safety and efficacy of interferon alfa-2b in the adjuvant treatment of uveal melanoma
OPHTHALMOLOGE. 2006; 103(6): 506-511. Doi: 10.1007/s00347-006-1350-7
Web of Science PubMed FullText FullText_MUG

** Zalaudek, I; Grinschgl, S; Argenziano, G; Marghoob, AA; Blum, A; Richtig, E; Wolf, IH; Fink-Puches, R; Kerl, H; Soyer, HP; Hofmann-Wellenhof, R Age-related prevalence of dermoscopy patterns in acquired melanocytic naevi.
Br J Dermatol. 2006; 154(2):299-304 Doi: 10.1111/j.1365-2133.2005.06973.x
Web of Science PubMed FullText FullText_MUG Google Scholar

Short report/Letter

** Richtig, E; Leinweber, B; Ghanimi, Y; Pölt, P; DiStefani, A; Hofmann-Wellenhof, R Speckled posttraumatic hyperpigmentation by foreign bodies on the lower legs after welding.
ARCH DERMATOL. 2006; 142(6): 790-792. Doi: 10.1001/archderm.142.6.790 (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** Richtig, E; Smolle, J Calculated tumour volume as a prognostic parameter for survival in choroidal melanomas - Reply to E Kujala and P Toivonen
EYE. 2006; 20: 124-125. Doi: http://dx.doi.org/10.1038/sj.eye.6701808 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

2005

Full paper/article (Journal)

** Boldin, I; Langmann, G; Richtig, E; Schwantzer, G; Ardjomand, N; Wegscheider, B; El-Shabrawi, Y Five-year results of prognostic value of tyrosinase in peripheral blood of uveal melanoma patients.
MELANOMA RES. 2005; 15(6): 503-507. Doi: 10.1097/00008390-200512000-00004
Web of Science PubMed FullText FullText_MUG

** Gerger, A; Koller, S; Kern, T; Massone, C; Steiger, K; Richtig, E; Kerl, H; Smolle, J Diagnostic applicability of in vivo confocal laser scanning microscopy in melanocytic skin tumors.
J INVEST DERMATOL. 2005; 124(3): 493-498. Doi: 10.1111/j.0022-202X.2004.23569.x [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

** Gruber, MJ; Wackernagel, A; Richtig, E; Koller, S; Kerl, H; Smolle, J Digital image enhancement for in vivo laser scanning microscopy.
SKIN RES TECHNOL. 2005; 11(4): 248-253. Doi: 10.1111/j.0909-725X.2005.00128.x
Web of Science PubMed FullText FullText_MUG Google Scholar

** Richtig, E; Ludwig, R; Kerl, H; Smolle, J Organ- and treatment-specific local response rates to systemic and local treatment modalities in stage IV melanoma.
BRIT J DERMATOL. 2005; 153(5): 925-931. Doi: 10.1111/j.1365-2133.2005.06796.x
Web of Science PubMed FullText FullText_MUG

** Richtig, E; Soyer, HP; Posch, M; Mossbacher, U; Bauer, P; Teban, L; Svolba, G; Wolf, IH; Fritsch, P; Zelger, B; Volc-Platzer, B; Gebhart, W; Mischer, P; Steiner, A; Pachinger, W; Hintner, H; Gschnait, F; Rappersberger, K; Pilarski, P; Pehamberger, H; European Cooperative Adjuvant Melanoma Treatment Study Group Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.
J Clin Oncol. 2005; 23(34):8655-8663 Doi: 10.1200/JCO.2004.00.8128 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

Abstract (Journal)

** Richtig, E; Soyer, HP; Posch, M; Mossbacher, U; Bauer, P; Fritsch, P; Pilarski, P; Pehamberger, H Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant combination therapy of interferon alfa and isotretinoin with adjuvant therapy of interferon alfa in patients with primary melanoma in stage IIA and IIB AJCC/UIC
J CLIN ONCOL 2005 23: 713S-713S.
Web of Science

2004

Full paper/article (Journal)

** Richtig, E; Hofmann-Wellenhof, R; Pehamberger, H; Forstinger, Ch; Wolff, K; Mischer, P; Raml, J; Fritsch, P; Zelger, B; Ratzinger, G; Koller, J; Lang, A; Konrad, K; Kindermann-Glebowski, E; Seeber, A; Steiner, A; Fialla, R; Pachinger, W; Kos, C; Klein, G; Kehrer, H; Kerl, H; Ulmer, H; Smolle, J Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.
BRIT J DERMATOL. 2004; 151(1): 91-98. Doi: 10.1111/j.1365-2133.2004.06019.x
Web of Science PubMed FullText FullText_MUG

** Richtig, E; Langmann, G; Müllner, K; Richtig, G; Smolle, J Calculated tumour volume as a prognostic parameter for survival in choroidal melanomas.
EYE. 2004; 18(6): 619-623. Doi: 10.1038/sj.eye.6700720 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

** Richtig, E; Langmann, G; Müllner, K; Smolle, J Ocular melanoma: epidemiology, clinical presentation and relationship with dysplastic nevi.
OPHTHALMOLOGICA. 2004; 218(2): 111-114. Doi: 10.1159/000076146
Web of Science PubMed FullText FullText_MUG

** Wolf, IH; Richtig, E; Kopera, D; Kerl, H Locoregional cutaneous metastases of malignant melanoma and their management.
Dermatol Surg. 2004; 30(2 Pt 2):244-247 Doi: 10.1111/j.1524-4725.2004.30091.x
Web of Science PubMed FullText FullText_MUG Google Scholar

Abstract (Journal)

** Gerger, A; Koller, S; Steiger, K; Massone, C; Kern, T; Richtig, E; Smolle, J Diagnostic applicability of in vivo confocal laser scanning microscopy in melanocytic skin tumors
J INVEST DERMATOL 2004 123: -.
Web of Science

** Kolm, I; Di Stefani, A; Zalaudek, I; Fink-Puches, R; Wolf, IH; Richtig, E; Gerger, A; Smolle, J; Kerl, H; Hofmann-Wellenhof, R Dermoscopic classification and follow-up of halo nevi
J INVEST DERMATOL 2004 123: 395-395.
Web of Science

** Zalaudek, I; Grinschgl, S; Richtig, E; Wolf, IH; Blum, A; Argenziano, G; Kerl, H; Soyer, HP; Hofmann-Wellenhof, R Age-related dermoscopic prevalence of Clark nevi
J INVEST DERMATOL 2004 123: 390-390.
Web of Science

2003

Full paper/article (Journal)

** Boogaerts, M; Coiffier, B; Kainz, C; Epoetin beta QOL Working Group Impact of epoetin beta on quality of life in patients with malignant disease.
Br J Cancer. 2003; 88(7):988-995 Doi: 10.1038/sj.bjc.6600801 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

** Richtig, E; Hoff, M; Rehak, P; Kapp, K; Hofmann-Wellenhof, R; Zalaudek, I; Poschauko, J; Uggowitzer, M; Kohek, P; Smolle, J Efficacy of superficial and deep regional hyperthermia combined with systemic chemotherapy and radiotherapy in metastatic melanoma.
J Dtsch Dermatol Ges. 2003; 1(8):635-642 Doi: 10.1046/j.1610-0387.2003.03719.x
PubMed FullText FullText_MUG Google Scholar

** Wolf, IH; Smolle, J; Binder, B; Cerroni, L; Richtig, E; Kerl, H Topical imiquimod in the treatment of metastatic melanoma to skin.
Arch Dermatol. 2003; 139(3):273-276 Doi: 10.1001/archderm.139.3.273 (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

** Zalaudek, I; Horn, M; Richtig, E; Hödl, S; Kerl, H; Smolle, J Local recurrence in melanoma in situ: influence of sex, age, site of involvement and therapeutic modalities.
Br J Dermatol. 2003; 148(4):703-708 Doi: 10.1046/j.1365-2133.2003.05155.x
Web of Science PubMed FullText FullText_MUG Google Scholar

Short report/Letter

** Zalaudek, I; Leinweber, B; Richtig, E; Smolle, J; Hofmann-Wellenhof, R Cutaneous zosteriform melanoma metastases arising after herpes zoster infection: a case report and review of the literature.
Melanoma Res. 2003; 13(6):635-639 Doi: 10.1097/01.cmr.0000056279.15046.c5 (- Case Report)
Web of Science PubMed FullText FullText_MUG Google Scholar

2002

Full paper/article (Journal)

** Aigner, RM; Schwarz, T; Richtig, E Malignant melanoma: diagnostic value of F-18 FDG positron emission tomography.
Wien Med Wochenschr. 2002; 152(11-12):286-288 Doi: 10.1046/j.1563-258X.2002.02023.x
PubMed FullText FullText_MUG

** Kränke, B; Richtig, E; Aberer, W Exanthema with eosinopenia.
Allergy. 2002; 57(1): 57-58. Doi: 10.1034/j.1398-9995.2002.1n3440z.x (- Case Report) [OPEN ACCESS]
PubMed FullText FullText_MUG

** Richtig, E; Regauer, S; Jakse, R; Anderhuber, W; Smolle, J Primary sinu-nasal melanomas. Clinical aspects, therapy and follow-up
Hautarzt. 2002; 53(2):106-113 Doi: 10.1007%2Fs00105-001-0307-7
Web of Science PubMed FullText FullText_MUG Google Scholar

Abstract (Journal)

** Richtig, E; Schlemmer, G; Mullner, K; Bergthaler, P; Papaefthymiou, G; Langmann, G; Smolle, J Uveal melanoma - Adjuvant therapy with interferon alpha 2 b
J INVEST DERMATOL 2002 119: 757-757.
Web of Science

** Rudolph, CM; Furstner, M; Richtig, E; Hofmann-Wellenhof, R; Kerl, H Evaluation of risk factors for malignant melanoma in 210 marathon runners
J INVEST DERMATOL 2002 119: 248-248.
Web of Science

2000

Full paper/article (Journal)

** Woltsche-Kahr, I; Komericki, P; Kränke, B; Brabek, E; Horn, M; Schuller-Petrovic, S; Richtig, E; Aberer, W Anaphylactic shock following peritumoral injection of patent blue in sentinel lymph node biopsy procedure.
Eur J Surg Oncol. 2000; 26(3):313-314 Doi: 10.1053/ejso.1999.0888 (- Case Report)
Web of Science PubMed FullText FullText_MUG Google Scholar

Short report/Letter

** Hofmann-Wellenhof, R; Soyer, HP; Richtig, E; Wolf, IH; Smolle, J; Scherer, C; Kerl, H Should dermatologists go public? A skin cancer screening campaign at recreation centers.
Arch Dermatol. 2000; 136(7):938-940 Doi: 10.1001/archderm.136.7.938 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

1998

Full paper/article (Journal)

** Regauer, S; Anderhuber, W; Richtig, E; Schachenreiter, J; Ott, A; Beham, A Primary mucosal melanomas of the nasal cavity and paranasal sinuses. A clinicopathological analysis of 14 cases.
APMIS. 1998; 106(3):403-410 Doi: 10.1111/j.1699-0463.1998.tb01364.x
Web of Science PubMed FullText FullText_MUG

** Smolle, J; Okcu, A; Hofmann-Wellenhof, R; Pfaffenthaler, E; Fink-Puches, R; Richtig, E; Kerl, H Automated measurement of melanoma cross-sectional area.
Am J Dermatopathol. 1998; 20(2):155-159 Doi: 10.1097%2F00000372-199804000-00009
Web of Science PubMed FullText FullText_MUG Google Scholar

Abstract (Journal)

** Hofmann-Wellenhof, R; Richtig, E; Amann, W; Hoff, M; Smolle, J; Kerl, H Hyperthermia as adjuvant therapy for metastatic malignant melanoma of the skin
BRIT J CANCER 1998 77: 30-30.
Web of Science

** Regauer, S; Anderhuber, W; Richtig, E; Schachenreiter, J; Ott, A; Beham, A Primary sinonasal melanomas. A clinicopathological study
BRIT J CANCER 1998 77: 31-31.
Web of Science

1997

Full paper/article (Journal)

** Schaider, H; Rech-Weichselbraun, I; Richtig, E; Seidl, H; Soyer, HP; Smolle, J; Kerl, H Circulating adhesion molecules as prognostic factors for cutaneous melanoma.
J Am Acad Dermatol. 1997; 36(2 Pt 1):209-213 Doi: 10.1016/S0190-9622(97)70282-2
Web of Science PubMed FullText FullText_MUG Google Scholar

1995

Abstract (Journal)

** Amann, W; Hoff, M; Steindorfer, P; Glanzer, H; Richtig, E; Geyer, E Local tumor control with microwave hyperthermia (MWHT) in advanced tumor disease
EUR J CANCER 1995 31A: 882-882.
Web of Science

** SCHAIDER, H; WEICHSELBRAUN, I; RICHTIG, E; SMOLLE, J; KERL, H NO DIFFERENCE IN LEVELS OF SOLUBLE HUMAN ICAM-1, PECAM-1, CD44 STANDARD, AND SPLICE VARIANTS V5, V6, AND V10 IN PATIENTS WITH AND WITHOUT PRIMARY TUMORS OF MALIGNANT-MELANOMA (PMM)
J INVEST DERMATOL 1995 105: 520-520.
Web of Science

1992

Full paper/article (Journal)

** Smolle-Juettner, FM; Smolle, J; Richtig, E; Kraus, I; Popper, H; Becker, H Primitive neuroectodermal tumor arising in the skin. Differentiation from neuroendocrine carcinoma of the skin.
Dermatology. 1992; 185(4):272-275 Doi: 10.1159/000247467 (- Case Report)
Web of Science PubMed FullText FullText_MUG Google Scholar

1991

Full paper/article (Journal)

** Rieger, E; Soyer, HP; Kofler, R; Hödl, S; Smolle, J; Richtig, E; Kerl, H Clinical epidemiologic data of malignant melanoma based on 1,368 patients of the Graz University Dermatology Clinic (1970-1989)
WIEN KLIN WOCHENSCHR 1991 103: 612-616.
Web of Science PubMed Google Scholar

↑ Top of page / Navigation